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Chapter 1 
General introduction 
Aims and outline of investigations. 

Cystic Fibrosis (CF) is the most prevalent fatal inherited disease in Caucasians. A 
change towards more aggressive treatment in children has lengthened their life expectancy 
and many patients survive into adolescence (1). 
In 2% the diagnosis is only made after the age of 18. Recognition of CF in a 69-
year-old man (2), a 65-year-old woman (3) and a 70-year-old woman (4) has been des-
cribed in recent reports. 
Where during infancy abdominal problems predominate, respiratory disorders 
become prominent in later life and usually is the limiting factor for a good quality of life. 
Eventually, more than 90 per cent of all CF patients die of respiratory insufficiency (5). 
The respiratory physician will therefore increasingly be involved in the care of adult CF 
patients. Nevertheless, disorders of the pancreas, the liver, the gut and the gallbladder 
can also lead to complaints in adults and even be life-threatening as in distal intestinal 
obstruction syndrome. Hence, gastroenterologists will also be consulted more often by CF 
patients. 
The recent localisation of the CF gene on chromosome 7 in 1989 (6) has had 
major implications for future research and possible therapy. The CF gene product -
known as the cystic fibrosis transmembrane conductance regulator (CFTR) - specifies a 
membrane transport protein. In 70% of Northern European and American patients a 
deletion of phenylalanine on position 508 ( delta-F508) is the CF mutation, but over 100 
other mutations have now been identified (7). 
Part of the clinical variation seen among CF patients can be attributed to differen-
ces in CF gene mutations. The majority of delta-F508 homozygotes have pancreatic 
insufficiency , but this relation is not absolute since adult patients with this genotype have 
been reported without pancreatic insufficiency (7). Moreover, a wide range of severity of 
pulmonary disease was seen among delta-F508 homozygotes, which suggests that 
environmental or other genetic factors contribute significantly to the variability in 
pulmonary and other complications seen among individuals with CF (8). Accepting that 
outcomes in CF are principally determined by gene mutations would be a fatalistic 
approach to management, because in that case it would be assumed that the genes have 
the last word. The documented clinical improvement of CF patients during the past 
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decades indicates that disease progress can be substantially attenuated by non-genetic 
factors (9). 
The growing number of adult CF patients presented by pediatricians to pulmono-
logists and gastroenterologists has involved these specialists into management, care and 
research of this complicated disease. 
The mean age of patients in most reported studies on CF disease is below 18. The 
general aim of this thesis is the investigation of functional aspects of the respiratory and 
digestive tract in adult CF patients. 
In Chapter 3, a retrospective analysis of gastroenterological disorders in adult CF patients 
is described and, in addition, relevant new insights on gastroenterologie aspects of CF 
are discussed. 
In Chapter 4 a review of the literature on pulmonary disorders in CF is given. 
In Chapter 5 the exocrine and endocrine functions of the pancreas and the morphologic 
characteristics of the pancreas as determined by ultrasound were studied in adult CF 
patients and compared with those in a group of normal control subjects. Cholecystokinin 
is a key factor in the regulation of digestive functions of the upper gastrointestinal tract. 
Since abnormalities in plasma cholecystokinin secretion and gallbladder emptying may 
contribute to the development of maldigestion and the formation of gallstones in CF, basal 
and postprandial plasma cholecystokinin levels and gallbladder volumes were determined 
in CF and compared with those in normal subjects. This study is described in Chapter 6. 
Most CF patients are suffering from recurrent pulmonary infections, which mostly leads 
to a decline in pulmonary function. Chapters 7 and 8 report on various measurements of 
lung function, the dose-dependent effects of different bronchodilators, the presence of 
bronchial hyperresponsiveness to histamine and exercise and the incidence of atopy in 
adult CF patients. A double-blind study to evaluate the effects of inhaled steroids on 
bronchial hyperresponsiveness to histamine in CF patients is described in Chapter 9. 
References 
1. D.J. Shale. Cystic Fibrosis. Thorax 1990;45:880. 
2. S.A. Evensen. A 69-year-old man with chronic obstructive pulmonary disease, 
pancreatic insufficiency and elevated sweat electrolytes. Acta Med Scand 1981;-
209:141-143. 
3. C.T.Su, B.Beanblossom. Typical cystic fibrosis in an elderly woman. Am J 
Medicine 1989;86:701-703. 
4. P.v.Bieren, S.Overbeek, C.Hilvering. Cystic Fibrosis in a 70-year-old woman. 
Thorax 1992;47:202-203. 
5. R.B. Fick, P.C. Stilwell. Controversies in the management of pulmonary disease 
due to cystic fibrosis. Chest 1989;6:1319-1327. 
6. B.Kerem, J.M.Rommens, J.A.Buchanan. Identification of cystic fibrosis gene: 
genetic analysis. Science 1989;245:1073-1082. 
7. R.A.Knight. Genetics of Cystic Fibrosis. Br J Hosp Med 1992;47:502-506. 
8. W. Burke, M.Aitken, S.Chen, R.Scott. Variable severity of pulmonary disease in 
adults with identical cystic fibrosis mutations. Chest 1992;102:506-509. 
9. J.A. Dodge. Determinants of pancreatic and pulmonary status in cystic fibrosis 
Lancet 1991;337:5. 
5 

List of abbreviations 
ΑΒΡΑ ¡Allergie bronchopulmonary aspergillosis. 
AT-index :Airtrapping index. 
BT-PABA ¡Benzoyl-tyrosyl-para-aminobenzoic acid. 
CCK :Cholecystokinin. 
CF : Cystic fibrosis. 
COPD ¡Chronic obstructive pulmonary disease. 
DIOS ¡Distal intestinal obstruction syndrome. 
FEV-1 ¡Forced expiratory volume in one second. 
FVC ¡Forced vital capacity. 
sGaw ¡Specific airway conductance. 
IB ¡Ipratropium bromide. 
MEFV-curve ¡Maximal expiratory flow-volume curve. 
MEF-50 ¡Maximal expiratory flow when 50 % of the FVC remains to be expired. 
MEF-25 ¡Maximal expiratory flow when 25 % of the FVC remains to be expired. 
PA ¡Pseudomonas aeruginosa. 
PC-20 ¡Provocative concentration of histamine 
histamine causing a 20 % fall in FEV-1. 
PEFR ¡Peak expiratory flow rate. 
PI ¡Pancreatic insufficiency. 
PP ¡Pancreatic polypeptide. 
PS ¡Pancreatic sufficiency. 
Raw ¡Airway resistance. 
RV ¡Residual volume. 
SEM ¡Standard error of the mean. 
Τ ¡Terbutaline. 
TLC ¡Total lung capacity. 
UDCA ¡Ursodeoxycholic acid. 
VC ¡Vital capacity. 
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Patients with cystic fibrosis (CF) may develop a wide variety of gastrointestinal 
disorders. Pancreatic insufficiency is a prominent feature of CF and malabsorption 
syndrome is a characteristic clinical problem in children with CF. As patients get older, 
more of the intestinal disorders associated with CF may become clear but adults may also 
be subject to the digestive diseases which may affect any individual who does not have 
CF. 
The aim of this retrospective study in adult CF patients was to determine the presence, 
development and severity of intestinal pathology. 
In addition, some new insights relating to gastroenterological aspects of the disease are 
briefly reviewed. 
Patients and methods 
From 1966 until 1986, 20 patients with cystic fibrosis above the age of 18 were 
treated in the Nijmegen University Hospital. Most patients were treated by pulmonolo-
gists. The group consisted of 12 men and 8 women. At the time of the investigation, three 
patients, aged 18,25 and 33, had died of pulmonary complications. The mean age of the 
remaining patients was 27 (18-41). In 3 patients the diagnosis of CF was not made before 
the age of 18. Retrospective analysis was performed on the basis of the medical records 
of these 20 patients. Data were collected with respect to diseases of the pancreas, liver, 
gallbladder and intestine. The presence of steatorrhea ( > 7 g faecal fat / 24 h) and other 
features of maldigestion and pancreatic dysfunction were determined. Serum levels of the 
vitamins E and D were taken from the records. It was also recorded whether the patient 
had suffered from meconium ileus, rectal prolapse, intestinal invagination or distal intes-
tinal obstruction syndrome. Biochemical liver function tests and results of liver biopsies 
were investigated. Ultrasonography, cholangiography and histology gave information on 
abnormalities of gallbladder and biliary tract. 
Results 
The gastroenterological manifestations of CF in our patient group arc summarized in 
Table 3.1 
Pancreas: The mean age at which pancreatic insufficiency (PI) was determined, 
was 7 (range 0-32). Of the 20 patients 16 suffered from steatorrhea. None of them 
11 
experienced an episode of pancreatitis. Of the remaining 4 patients with pancreatic 
sufficiency (PS) 2 had suffered from recurrent pancreatitis. In 3 patients with PS who had 
been classified as such on the basis of a normal faecal fat excretion, a decreased urinary 
excretion of p-aminobenzoic acid (PABA) after oral administration of n-benzoyl-1-tyrosyl-
p-aminobenzoic acid (n-BT-PABA) suggested the presence of a moderate impairment of 
exocrine pancreatic function. In 3 patients with steatorrhea diabetes mellitus developed at 
the ages of 23, 24 and 26. Patients with normal faecal fat excretion did not suffer from 
diabetes mellitus. Lowered serum levels of vitamin D ( 25-OH-D3) were present in 6 of 
7 patients with PI. The vitamin E levels were decreased in all 15 patients with PI. None 
of the patients with PS had lowered levels of vitamin E or D. 
Intestine: None of the patients had neonatal meconium ileus. Three patients 
suffered from rectal prolapse at the ages of 1,1 and 3. Four patients clearly showed 
episodes of a distal intestinal obstruction syndrome. In one patient rectal enema with 
gastrografin was performed to relieve obstructive ileus with success. 
Liver: Disturbed biochemical liver function tests were observed in 9 patients. In 5 
patients focal biliary cirrhosis was documented at liver biopsy or suspected from the 
presence of portal hypertension, hypersplenism and splenomegaly. The age at which liver 
cirrhosis was demonstrated ranged from 15-33 ( mean age 19 ). In one patient liver 
disease was the presenting sign of CF disease. Icterus was not observed in any of our 
patients. Bleeding from esophageal varices occurred in 2 patients. In one patient splenec-
tomy and splenorenal shunting were performed, the other patient underwent portacaval 
shunting and died within 3 years after the operation. 
Gallbladder and biliary tract: Fourteen patients were investigated by means of 
ultrasonography. This revealed concrements in the gallbladder in 4 patients and micro-
gallbladders in 5 patients. None of the patients suffered from cholecystitis or bile duct 
obstruction. 
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FREQUENCY(%) 
EXOCRINE PANCREATIC INSUFFICIENCY 
PANCREATITIS 
DECREASED URINARY PABA-EXCRETION 
DIABETES MELLITUS 
DECREASED SERUM LEVELS OF VITAMIN D 
DECREASED SERUM LEVELS OF VITAMIN E 
RECTAL PROLAPSE 
DISTAL INTESTINAL OBSTRUCTION SYNDROME 
LIVER DISORDERS 
CHOLELITHIASIS 
Table 3.1: gastroenterological manifestations of cystic fibrosis (n=20). 
Discussion 
In cystic fibrosis serious and extensive abnormalities of the digestive tract can 
occur (1-4). Symptoms of liver, pancreatic and intestinal disease may present before or 
after the occurrence of respiratory symptoms (4). Exocrine pancreatic insufficien-
cy is present in 80-85 % of the adult CF patients (1,3). The exocrine function of the 
pancreas depends on the epithelial transport of anions to move water across membranes 
into secretions. The abnormally viscous secretion gives rise to obstructive plugging, ductal 
obstruction and subsequent damage of pancreatic tissue (3). The degree of pancreatic 
destruction is highly variable. A significant influence of the particular genotypical 
abnormality on pancreatic function has been found. The majority of the delta-F508 
homozygotes have pancreatic insufficiency (5,6) but a few adults with pancreatic sufficien-
cy have been reported with the same genotype , suggesting that non-genetic factors also 
play a role in disease expression (7,8). Pancreatic sufficiency mainly occurs in patients 
with mild mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) 
80 
10 
100 
15 
85 (n=7) 
100(n = 15) 
15 
20 
25 
20 
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gene, such as R 117H, R 334W, R 347P,A 455E and Ρ 574H (6). It is becoming clear 
thai some patients with pancreatic sufficiency do show progressive destruction of exocrine 
tissue and loss of function; these patients may eventually require pancreatic enzyme 
supplementation (6). The finding in the present study of acute or recurrent 
pancreatitis in patients with pancreatic sufficiency is a well described complication in 
older patients (9,10). In fact, cystic fibrosis should be considered in all patients with 
unexplained recurrent pancreatitis. Succesful management of exocrine pancreatic 
insufficiency in the presence of normal dietary fat intake can usually be achieved with the 
modern pancreatic enzyme supplements (11-16). These enteric-coaled microsphere 
formulations allow the CF patient to take a high-energy diet without any restrictions (16). 
Occasionally, pharmacological inhibition of gastric acid secretion with H2-receptor 
antagonists or proton pump inhibitors like Omeprazol are needed to obtain optimal digesti­
on (17-23). 
Deficiency of fat-soluble vitamins can occur in the presence of steatorrhea. 
Vitamin E is important for normal neurological function in man (24). As we and others 
demonstrated, CF patients with pancreatic insufficiency tend to have reduced serum 
concentrations of vitamin E and are therefore at risk of developing the neurological 
complications associated with vitamin E deficiency (25,26). Several CF patients have been 
reported to have serious neurological diseases such as spinocerebellar syndrome, retinopa­
thy, ophthalmoplegia, muscle weakness and sensory disturbances due to vitamin E 
deficiency (27,28). Sensitive neurological function tests detected abnormalities in CF 
patients with low serum vitamin E levels and otherwise unremarkable clinical neurological 
examinations (29). Supplementation of vitamin E to achieve normal serum concentrations 
can thus be strongly recommended. Serum vitamin D levels also appear to be reduced in 
CF patients (30-35). Especially low exposure to sunlight in older, more sedentary CF 
patients may place them at risk of clinical vitamin D deficiency (32,34,35). Serum 25-
OH-D3 levels ( and not serum l,25-diOH-D3 levels) should be monitored regularly in 
adult CF patients (33). Exposure to sunlight and supplementation of vitamin D is advised 
to achieve normal 25-OH-D3 levels. The position with vitamin A is more problematical. 
The serum vitamin A concentrations do not reflect hepatic stores accurately so that it is 
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possible that too much supplementation causes hypervitaminosis A which can give toxic 
liver injury. Nevertheless, clinical manifestations of vitamin A deficiency like night 
blindness and conjunctival xerosis have been reported in several CF patients (36,37). 
Rectal prolapse occurs in 20 % of CF patients, usually in the first years of life 
(2,3). Conservative management with adequate pancreatic enzyme substitution is succesful 
and surgical intervention is rarely indicated (3). 
The distal intestinal obstruction syndrome (DIOS) was observed in 20 % of our 
adult patients. It is characterized by repeated painful attacks of intestinal obstruction and 
its presence is limited to patients with pancreatic insufficiency (2,3,4). These symtpoms 
are caused by inspissation and poor clearance of concentrated, dehydrated intestinal 
contents secondary to inadequately controlled pancreatic insufficiency (38-41). A prolon-
ged intestinal transit time may also contribute to this disorder (42). DIOS can be treated 
conservatively in most patients by increasing pancreatic enzyme supplementation, H2-
receptor antagonists, acetylcysteine solution and rectal enema with gastrografin (39,41). 
In some centres intestinal lavage solutions are used with success (42,43). Cisapride was 
not found to have relevant beneficial effects in the treatment of DIOS (45,46). 
As demonstrated in our patient group, liver disorders may be the first clinical 
manifestation of cystic fibrosis but early liver disease is asymptomatic in most patients. 
Standard biochemical liver function tests correlate poorly with clinical evidence of the 
liver disorders (47). The prevalence of overt liver disorders is 2-5 % (2,47). In contrast to 
earlier reports, a recent large epidemiological study showed that the age-related prevalen-
ce decreased in patients over the age of 20 years (47). Deaths from liver disorders were 
rare, possibly because the presence of liver disease is associated with earlier respiratory 
death in young CF patients (47). Little is known of the pathogenesis, prevention or 
treatment of liver disorders in cystic fibrosis (4). It is also unknown why significantly 
more male CF patients are affected by liver disorders (47). Unfortunately, the localization 
of CFTR in normal liver has proven difficult and the fundamental CF defect in the liver 
still remains unknown (1). The development of liver disorders in CF does not seem to 
be associated with a specific gene mutation and enviromental factors are probably 
involved in its pathogenesis (5,48). Focal biliary fibrosis and multilobular biliary 
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cirrhosis are the characteristic histological lesions in the CF liver (3). Due to its focal 
distribution, a liver biopsy can yield false negative results and hepatic insufficiency only 
occurs at a late stage of the disease (49-51). The management of hepatic failure, portal 
hypertension and varicosal bleeding from oesophageal varices is similar as in patients 
without cystic fibrosis. Sclerotherapy of varices and liver transplantation have been 
accomplished with success in CF patients (51,52). It has been suggested that liver 
disorders in CF may be due to common-bile-duct stenosis secondary to pancreatic fibrosis 
(53). In contrast to this report, however, recent studies indicated that intrahepatic biliary 
duct abnormalities were present in CF-related liver disease but common-bile-duct 
strictures were not found to contribute to either the progression or development of liver 
disease in these patients (54,55). Therapy with ursodeoxycholic acid (UDCA) has been 
reported to improve biochemical liver function tests in CF patients (56-59). However, 
long-term controlled studies with UDCA will be required to demonstrate an effect on liver 
disorders portal hypertension and mortality. At present it is too early to advocate UDCA 
administration as an established form of therapy for CF patients and associated liver 
disorders. 
Gallbladder abnormalities are seen in up to 45 % of CF patients (2,49,50). 
"Microgallbladder" or non-visualized gallbladders on ultrasonography are often described. 
Gallstones are found in 4-12 % of CF patients (2,4,50). Symptomatic gallbladder disease 
was observed in only 4 % of a large studied group (60). Cholecystectomy can be 
performed with relative safety if careful perioperative care is provided (60-62). Although 
cholelithiasis is therefore not a serious clinical problem, it raises pathophysiological 
questions. Excessive faecal loss of bile acids may lead to a reduction in bile acid pool 
size, a rise in cholesterol saturation of bile and subsequently lithogenic bile in CF patients 
(49,63). 
Many other digestive diseases have been described in CF patients. Gastro-
oesophageal reflux seems to be more common in CF patients than expected and may 
contribute to the progression of pulmonary disease in some CF patients (64-67). 
Inappropriate relaxation of the gastro-oesophageal sphincter has been implicated as a cause 
of gastro-oesophageal reflux in cystic fibrosis (68). Hyperinflation of the lungs, causing 
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depression of the diaphragm, could impair the antireflux mechanism of the oesophageal 
hiatus (69). In addition, gastric acid hypersecretion might further facilitate the occurrence 
of gastro-oesophageal reflux in CF patients (70). 
Other digestive diseases reported in patients with cystic fibrosis include: coeliac disease 
(71), giardiasis (72,73), Crohn's disease (73-76), pneumatosis intestinalis (77) and 
intestinal adenocarcinomata (78-84). As the survival of CF patients improves, they will 
be liable to the same spectrum of digestive diseases as healthy adults. 
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Chapter 4 
Aspects of pulmonary disorders in cystic fibrosis. 
A review of the literature. 

As a result of better control of nutrition and improved therapy of lung disease, 
most patients with cystic fibrosis (CF) reach adult life (1). A wide range of severity is 
seen and considerable differences exist between patients in the rate at which respiratory 
function declines. Part of the clinical variation may be attributed to various CF gene muta-
tions (2). However, marked differences in pulmonary disease among identical CF 
genotypes are strong evidence for the modifying influence of other factors on disease 
severity (2,3). 
The lungs in CF are morphologically normal at birth, and the onset of pulmonary 
pathology may occur any time after birth. By the time patients enter adulthood, only 2 per 
cent lack clinical evidence of pulmonary disease (4). Autopsy studies indicate that the 
airway pathology is irregularly distributed with the upper lobe segments disproportionately 
more involved (5). Recent investigations with high-resolution computed tomography in 
adult CF patients with mild pulmonary disease confirm that abnormalities in the upper 
lobes are the earliest features of lung involvement (6). 
Light and electron microscopic studies have failed to identify a single pulmonary lesion 
specific for CF. Submucosal gland hypertrophy, duct obstruction and mucus cell hyperpla-
sia occur at an early stage. These abnormalities encourage colonisation of the respiratory 
tract with microorganisms. Abnormalities first occur in the small airways and include 
bronchiolitis with mucus impaction and cyst formation. Ultimately destruction of tissue in 
the walls of airways give rise to bronchiectasis, which has been observed in children as 
young as 2 months (7). This leads to a vicious circle of endobronchial and endobronchio-
lar infection and inflammation with impaired ciliary function and reduced clearance of 
mucus (8). Further bronchial damage occurs, leading to obstruction and hyperinflation 
which are prominent at necropsy. Figure 4.1 shows the negative interactions in the 
development and progression of lung disease in CF. Hypoxemia is presumably responsible 
for the pulmonary hypertension and resultant cor pulmonale. Overt right-sided heart 
failure accelerates the deterioration of the patient's condition (9). 
Abnormalities in pulmonary function parallel and reflect the pathological proces-
ses. The most sensitive tests in an early stage of the disease are those detecting small 
airway involvement, such as the MEF-50 and MEF-25 values derived from maximal 
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expiratory flow volume (MEFV) curves. In a more advanced stage of the disease, an 
increase in airway resistance (Raw) and a decrease in FEV-1 and in the ratio FEV-l/VC 
reflect large airways and/or extensive small airways involvement (10). Total lung 
capacity (TLC) remains within normal limits until extensive lung damage is present, when 
TLC becomes reduced due to widespread fibrosis. A restrictive pattern of pulmonary 
function can be seen in some patients but this does not necessarily indicate more severe 
disease (11). Bronchodilator responsiveness is reported in 0-43 % of children with CF 
(12-14). A paradoxical reduction in airflow after bronchodilator administration has been 
reported in some children with CF (15). The combination of sympathomimetics and 
theophylline shows no advantage over sympathomimetics alone and in some patients 
(obviously with airway wall instability) the drug combination had a destabilizing effect 
which led to airway compression, although these findings have only been reported by a 
single author (16). Oral theophylline therapy has no beneficial effect on lung function but 
can improve nighttime oxygen saturation in selected patients (17). However, significant 
sleep disruption, increased wakefulness and decreased sleep efficiency occur with theop-
hylline therapy in CF, impeding its usefulness (17). Nocturnal hypoxaemia only occurs in 
severely affected CF subjects (18,19). In a 3-year double-blind, placebo- controlled, 
randomized study in a small CF population, nocturnal oxygen treatment alleviated the 
desaturation but did not affect mortality, exacerbation rate and disease progression 
(20,21). The studied group, however, might have been too small to detect significant 
changes. It is also possible that the pulmonary vascular bed is more destructed instead of 
vasoconstricted in hypoxemic CF patients. Further studies on the efficacy of oxygen 
therapy on CF patients are needed. 
Chest radiographs may be normal in mild disease. An early radiologic abnormality 
is peribronchial thickening in the upper zones (22). Hyperinflation, areas of collapse or 
consolidation and bronchiectasis can be seen in an advanced stage of the disease. 
28 
Figure 4.1: Interactions in development and progression of lung disease in cystic 
fibrosis. 
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Worsening of pulmonary function occurs during infective exacerbations. Staphylo-
coccus aureus and haemophilus influenzae are the predominant pathogens in young 
children with CF, whereas in a later stage pseudomonas aeruginosa ( PA ) becomes the 
most important colonizing organism (22). The presence of haemophilus can be obscured 
by the presence of faster growing organisms unless selective culture media are used (23). 
Most CF patients will eventually acquire chronic PA infection of the lung. Siblings with 
CF often carry the same strain of PA, indicating cross-infection or colonization from the 
same enviromental source (24). Cross-infection also may occur in CF treatment centres 
(25). Injury to epithelial cells after inflammatory damage by viruses or bacteria such as 
staphylococcus aureus, might predispose to PA infection (25,26). The course of chronic 
PA infection varies greatly in individual patients: survival ranges from a few years to 20 
years after detection of PA (27). Acquisition of PA does not cause an immediate and rapid 
deterioration in CF and the justification of the effort aimed toward eradication of PA is 
questioned (28). Vaccination of non-infected patients with a polyvalent PA vaccine has 
been tried without success (29). Chronic PA infection is characterised by a pronounced 
antibody response without detectable increase in cell-mediated immunity (30). Despite 
heavy prolonged colonization, systemic spread of PA is limited. There are only few 
reports of PA bacteraemia in CF patients (31-33). The incidence of bacteraemia and 
fungacmia increases with the use of implantable venous access systems and central venous 
catheters (33,34). PA strains in upper airway reservoirs, such as the paranasal sinus, 
appeared to be identical to the strains in the lung (35). Aggressive management of sinus 
disease may therefore alleviate respiratory symptoms in selected CF patients (36). 
Moreover, these sites should be screened and treated before lung transplantation to protect 
the donor lung from rapid acquisition of PA from the upper airways (35). 
Some authors have suggested a relation between viral infections and exacerbations 
of respiratory symptoms in CF (37-39). Others, however, could not confirm this associati-
on (40-41). Moreover, there is no evidence that viral infections are more common in CF 
patients (40,42). Viral infections may have a permissive effect on PA colonization (42) 
and the seasonal differences in occurrence of PA might be explained by a synergistic 
interaction with respiratory viruses (43,44). The relevance of human and atypical 
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mycobacterial infections in CF is still controversial. Only in a small minority of patients 
these infections are clinically important (45-48). 
In CF there is no convincing evidence suggesting a defect in host defence 
mechanisms, though there are incidental exceptions (49). As stated before, systemic 
spread of pulmonary infection is rare, despite the enormous bacterial load and sometimes 
debilitated clinical condition of the CF patient. The continuous antigenic stimulation 
produced by the persistence of organisms in the airways leads to a chronically over-active 
immune response. In fact, part of the lung damage might be caused by this host-immune 
hyperresponsiveness. High total IgG levels, and high antibody levels against Pseudomonas 
aeruginosa antigens are associated with poor clinical condition and severe lung function 
impairment, whereas low immunoglobulin levels are correlated with less severe pulmona-
ry disease (25,50-53). If the excessive immune response contributes to the tissue damage, 
it would implicate a new approach to therapy. Anti-inflammatory agents including 
Ibuprofen and methotrexate are under investigation (54,55). Inhaled corticosteroids, which 
are increasingly prescribed as anti-inflammatory agents in asthma and chronic obstructive 
pulmonary disease, have not been investigated in CF so far. This was the subject of the 
study presented in Chapter 9. 
In the future antielastase compounds, antioxidants and antagonists to cytokines 
might be new therapeutic modalities (49). Another consequence of exaggerated immune 
response is the occurrence of circulating immune complexes. These circulating immune 
complexes can be found in many CF patients (56-58). It is thought that immune com-
plexes may cause immune complex-mediated arthritis, vasculitis and purpura in CF (59-
61). Vasculitic rashes can be seen in CF patients with high IgG levels and severe lung 
disease and are associated with poor long-term survival (61). 
Important respiratory complications in CF include haemoptysis, pneumothorax and 
allergic bronchopulmonary aspergillosis. Massive haemoptysis occurs in approximately 
7 % of CF patients (62). Bronchial artery embolization can be performed succesfully and 
repeated when necessary (62-66). Vasopressor agents such as desmopressin and vasopres-
sin have a useful role as non-invasive therapy for severe haemoptysis, though temporarily 
(67). 
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The risk of pneumothorax increases during adolescent and adult life (68,69). A 
large pneumothorax requires drainage. When insufficient expansion is achieved, a 
considerable therapeutic dilemma is created. In the past extensive chemical or surgical 
plcurodcsis or pleurectomy has been advocated (68). This might interfere, however, with 
a succesful lung transplantation in the future. Currently it is recommended that a CF 
patient with recurrent pneumothoraces who might be a candidate for lung transplantation 
should be treated with a minimum of intervention: drainage, chemical pleurodesis, ligation 
of bullae or a limited surgical pleurodesis for instance with a video-assisted thoracoscope 
approach, in preference to thoracotomy and pleurectomy (70). 
Allergic bronchopulmonary aspergillosis (ΑΒΡΑ) is present in approximately 10 % 
of patients with CF (71-73). It is underdiagnosed since the underlying disease itself may 
be associated with exacerbations of wheeze and cough and infiltrates may be seen on the 
chest X-ray (74). ΑΒΡΑ is a potential cause of important lung damage. Prospective scree­
ning using well-defined criteria for ΑΒΡΑ could lead to earlier detection and prompt 
treatment may prevent lung damage not caused by bacteria (75). 
General treatment of respiratory disease consists of specific antimicrobial therapy, 
influenza vaccination and physiotherapy. The maintenance of a sufficient nutritional status 
and cardiopulmonary fitness are important issues in the clinical management (76). The 
importance of bronchodilator therapy is discussed in Chapters 7 and 8 of this thesis. 
Many patients use mucolytics administered by aerosol inhalation. They may subjectively 
feel that their sputum is more readily expectorated after inhaled mucolytics but controlled 
studies to support this, are lacking. Thus, the use of mucolytic therapy as a routine 
treatment is controversial. In selected patients acetylcysteine improved pulmonary function 
as demonstrated in a placebo-controlled study (77). Ciliary activity was not improved, so 
dampening of inflammation through inhibition of toxic oxygen radicals may have been the 
mechanism of this improvement (77). Long-term oral steroids improved the pulmonary 
function in a group of CF patients (78) but later prospective evaluation showed substan­
tial, unacceptable side-effects and complications in this patient group such as growth 
impairment, diabetes, early cataract and bone fractures (79,80). In the treatment of 
ΑΒΡΑ steroids are necessary with follow-up of disease parameters such as total IgE, 
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eosinophilia and chest radiograph. 
In a small subset of patients the pulmonary abnormalities may be localized in one 
(upper) lobe or lung segment. In selected cases patients could benefit from limited surgical 
pulmonary resections (81,82). However, this should not be performed in patients with 
localized disease but with an FEV-1 or FVC less than 30 % predicted, as this suggests 
diffuse pulmonary disease (82). 
The technical ability and practical skills to implement screening programmes for 
detection of CF carriers in the general population are now available although the ethical 
base of such an approach requires careful discussion (83). Early detection of CF patients 
provides an opportunity for more causal therapeutic approaches. Amiloride, an epithelial 
sodium channel blocker, has been shown to improve rheological properties of airway 
secretions (84). The decline in lung function was reduced by amiloride in a long-term trial 
(85). This raises the possibility that before respiratory symptoms have developed, 
prophylactic treatment for young patients may be worthwhile (84). Another experimental 
idea involves administering aerosol to the lungs of a normal CF-gene-DNA sequence 
using a vector derived from adenovirus. Currently, three trials for gene therapy in CF are 
under progress. Also undergoing clinical investigation is the efficacy of aerosol 
administration of recombinant human deoxyribonuclease (rhDNase). CF sputum contains 
increased amounts of DNA, released from degenerated leucocytes. The presence of DNA 
increases sputum viscosity and adherence and interferes with bacterial killing. Nebulised 
DNase removes the abnormal contribution of DNA to the viscosity of CF sputum by 
degrading the extracellular DNA. The results of prospective controlled studies of the 
influence of DNase on lung function and clinical course are now awaited. 
Since 1985 succesful heart-lung and double lung transplantations for CF patients 
have been performed (86,87). Lung transplantation is a viable option for the treatment of 
CF patients with end-stage lung disease and a short life-expectancy. Demands for this 
treatment from patients and their physicians are increasing as they become more aware of 
the encouraging outcome. However, shortage of suitable donor organs requires careful 
selection of recipients who would benefit from transplantation. There used to be concern 
that the genetic ion transport defect might develop in the donor lungs. However, in vivo 
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measurements of airway potential difference, which is characteristically increased (more 
negative) in CF patients (88), remained normal in the transplanted lungs up to two years 
after transplantation (89). However, the trachea above the anastomosis still retains the CF 
epithelial defect (90). This is in agreement with the finding that the genetically determined 
chloride channel defect is expressed at a cellular level in epithelium and not as a result of 
circulating mediators (91). Early morbidity after transplantation is high (87). The 
reported actuarial patient survival at 1 year ranges from 42 to 72 % (87,92-95). Patients 
and physicians should realise that lung transplantation is not a cure of the multisystem CF 
disease. Careful monitoring of rejection, infections and extrapulmonary disease remain 
essential for the rest of their lives. 
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Summary 
To determine the relation between pancreatic morphology and pancreatic exocrine and 
endocrine function we have studied 8 adult cystic fibrosis patients and 14 normal control 
subjects by ultrasonography and pancreatic function testing. In the patients with cystic 
fibrosis maximum anteroposterior diameter of the pancreatic head was significantly 
increased over that in control subjects (p < 0.01), whereas maximum diameter of the 
body was significantly decreased (p = 0.05). Increased echogenicity of the pancreatic 
body was observed in most patients. In the cystic fibrosis patients postprandial insulin 
secretion was reduced in the first hour (p < 0.005 vs control), while pancreatic polypepti-
de secretion was virtually abolished for at least 3 hours (p < 0.01 vs control ). All cystic 
fibrosis patients had evidence of exocrine pancreatic dysfunction as reflected by a 
diminished urinary paraaminobenzoic acid excretion. Intraduodenal enzyme and bicarbo-
nate output in response to secretin-cholecystokinin were reduced in 3 out of 3 patients 
studied. It is concluded that loss of endocrine and exocrine pancreatic function in adult 
cystic fibrosis patients are accompanied by a small and echodense pancreatic body relative 
to a large pancreatic head. 
Keywords: Cystic fibrosis, pancreas, pancreatic function, pancreatic polypeptide, 
paraaminobenzoic acid, insulin, steatorrhea, ultrasonography. 
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Introduction 
Improvement in diagnosis and therapy has lengthened life expectancy of children with 
cystic fibrosis (CF) and the majority of these patients now survive at least into ado-
lescence (1). The pulmonary disease dominates the clinical picture, but pancreatic 
involvement is responsible for exocrine and endocrine dysfunction in the adult population 
as well. The majority of adult CF patients have severe pancreatic insufficiency. However, 
approximately 15 % has normal faecal fat excretion (2). Diabetes mellitus occurs in about 
13 % of adults with CF (2). 
In the present study in adult CF patients, pancreatic exocrine and endocrine function as 
well as morphological characteristics of the pancreas as determined by ultrasound were 
compared with those in a group of normal control subjects. Detection of functional and 
morphologic pancreatic disturbances provides further understanding of the pathological 
process in this heriditary disease. Furthermore, the finding of pancreatic abnormalities can 
support the diagnosis of CF in patients with lung disease, suspected to have CF, but with 
non-informative or borderline sweat test results (3). 
Methods 
Eight patients (6 male, 2 female) with CF were enrolled in the study. The mean age of the 
patients was 28 (range 22-41). All patients had proven CF, confirmed by a sweat 
chloride level of > 70 mmol/L. Six patients had an increased faecal fat excretion ( range 
27-67 g / 24h ), whereas 
two patients did not have steatorrhea on repeated tests. None of the CF patients suffered 
from diabetes mellitus. Fourteen age-matched sex-matched healthy volunteers acted as 
control subjects. Informed consent was obtained from all subjects studied and the protocol 
was approved by the ethics committee of Nijmegen University Hospital. 
After an overnight fast ultrasound examination was performed using a real-time scanner 
with a 3.5 MHz transducer. Images of the pancreas were obtained according to the 
method described by Niederau (4). The maximum anteroposterior diameter of the head 
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and body of the pancreas were measured on a transverse oblique scan, using the upper 
abdominal blood vessels as landmarks (4). The patients were positioned for optimal 
visualization of the pancreas including supine and decubitus position. Seven patients and 8 
normal subjects during a 15 min period, ingested a standard breakfast consisting of 30 g 
fat, 30 g protein and 70 g carbohydrate. Two mmol of the synthetic peptide N-bcnzoyl-1-
tyrosyl-p-aminobcnzoic acid (BT-PABA) was added to the meal. Blood was drawn for 
measurement of glucose, insulin and pancreatic polypeptide before and at 15 min intervals 
until 180 min after start of the meal. After the meal, patients were not allowed to eat but 
were asked to drink at least 1,5 L water to guarantee a sufficient urine production which 
was collected for 6 hours after the meal. The recovery of paraaminobenzoic acid (PABA) 
was determined in 6-hours urine. Plasma insulin and pancreatic polypeptide (PP) were 
measured by radioimmunoassay (5,6) and PABA in urine by photometry (7). A secretin-
cholecystokinin stimulation test was performed in three patients, two with overt stea-
torrhea and one without steatorrhea. The duodenal output of amylase, trypsin and 
bicarbonate were measured and compared to normal values from our laboratory (8). 
Unless otherwise stated, results were expressed as the mean N 1 SD. Basal values were 
calculated by taking the mean of two fasting samples. Integrated plasma insulin secretion 
and integrated plasma PP secretion were determined by calculating the area under the 
plasma concentration-time curve, after subtraction of the basal value. Statistical analysis 
was performed by Student's t-test and the Mann-Whitney U-test. Spearman's rank order 
correlation coefficient was used to determine the correlation between pancreatic size 
measurements and the other parameters studied. All tests were two-tailed. 
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Figure 5.1 
Maximum anteroposterior diameter of the pancreatic head (left panel), the pancreatic body 
(middle panel) and the ratio of these dimensions (right panel) in 8 cystic fibrosis patients 
(hatched bars) and in 14 normal subjects (open bars). Error bars denote 1 SEM. 
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Figure 5.2 
Hourly integrated plasma pancreatic polypeptide secretion (upper panel) and hourly 
integrated plasma insulin secretion (lower panel) in 7 cystic fibrosis patients (hatched bars) 
and in 8 normal subjects (open bars). Error bars denote 1 SEM. 
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Results 
Maximum anteroposterior diameter of the pancreatic head in CF (31.0 ±_ 9.1 mm) was 
significantly larger than that in control subjects (22.5 +. 4.9 mm; ρ < 0.01; figure 5.1 ), 
whereas pancreatic body diameter was significantly smaller (11.4 ±_ 1.7 mm in CF versus 
13.0 ±_ 1.9 mm in control subjects; ρ = 0.05; figure 5.1 ). The ratio of pancreatic head 
and body diameter was significantly larger in the CF patients (2.8 ±_ 1.1) when compared 
to that in control subjects (1.8 ±_ 0.4; ρ < 0.005; figure 5.1). Ultrasonography of the 
pancreas revealed an increased echogenicity in 5 of the 7 patients. In one CF patient 
without a history of pancreatitis a homogeneous anechoic cavity with a diameter of 2 cm 
compatible with a small cyst was found in the head of the pancreas. 
Basal plasma PP level in CF (12 ±_ 3 pmol/L) was significantly (p < 0.05) lower than 
that in the control subjects (24 +. 14 pmol/L). In the control subjects meal ingestion 
evoked an immediate and statistically significant (p < 0.001) increase of plasma PP level 
to a peak value of 106 _+ 34 pmol/L at 75 minutes. On the other hand in the CF patients 
meal ingestion did not induce any significant change in plasma PP. Integrated plasma PP 
secretion in the CF patients was significantly lower than that in the control subjects until 3 
hours after the meal, (p < 0.01; figure 5.2 upper panel). Basal plasma insulin concentra­
tion was not significantly different between the CF patients (7.6 ±_ 3.7 mU/L ) and the 
normal subjects (11.3 +. 2.0 mU/L, ρ = 0.08). However, integrated plasma insulin 
secretion in response to meal ingestion was significantly lower in the first hour (p < 
0.005; figure 5.2, lower panel). This difference subsided in the second and third hour 
after the meal (figure 2, lower panel). Basal (4,2 ±_ 0.8 mmol/L) and maximum plasma 
glucose concentration (8.7 ±.2 .1 mmol/L) in CF patients were similar to that in normal 
subjects (3.9 ± 0.6 mmol/L and 7.6 ± 3.1 mmol/L respectively; NS). Urinary PABA 
excretion was reduced in all CF patients (19 ±_ 13%; range 8- 43 %) when compared to 
normal subjects (59 ± 17%; range 51-68 %; ρ < 0.005). 
The pancreatic body diameter was significantly correlated to urinary PABA excretion (p 
< 0.01), basal plasma PP concentration (p < 0.05) and maximum postprandial plasma 
PP level (p < 0.05). The results of the secretin-cholecystokinin stimulation test in 3 
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patients with CF are summarized in Table 5.1. 
Patient A B C 
Faecal fat excretion 67.1 27.4 2.7 
(g/24h) 
Maximum amylase concentration 1.2 0.3 42 
(% of normal) 
Maximum trypsin concentration 1.9 0.3 84 
(% of normal) 
Bicarbonate excretion 12.5 7.0 4.0 
(% of normal) 
Table 5.1: Secretin-cholecystokinin stimulation test. 
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Discussion 
Ultrasonographic examination of the pancreas in CF patients revealed a larger pancreatic 
head and a smaller pancreatic body when compared to normal subjects. Furthermore, the 
ratio of pancreatic head and body diameter in CF patients was much larger than that in 
normal subjects. The reason for these morphological characteristics of the pancreas in CF 
patients is not known. In chronic pancreatitis enlargement of the pancreas occurs initally 
and later in the course atrophy is seen (9). Theoretically it may be possible that the 
pathological process in CF has a more severe damaging effect on the body initially 
sparing the pancreatic head. During the development of damage to the pancreatic body, 
the pancreatic head may increase to compensate for loss of functioning pancreatic tissue. 
The finding of an increased echogenicity of the pancreatic body in most CF patients, 
which has been attributed to fibrosis and fatty replacement (10,11) together with the 
finding that selenomethionine (Se75) scanning of the pancreas in CF patients showed only 
uptake in the pancreatic head (12), supports this hypothesis. 
In one patient an anechoic cavity of 2 cm diameter, which was probably a cyst, was seen 
on sonography. Pancreatic cystosis is like fibrosis and steatosis a characteristic pathologic 
feature and the name "cystic fibrosis" is derived from these hallmarks (13). Pancreatic 
cysts in CF are true cysts, lined by a single layer of epithelium and contain inspissated 
eosinophilic material. The defective bicarbonate, chloride and fluid transport is thought to 
lead to intrapancreatic protein hyperconcentration, stasis and secondary ductal ectasia 
(14). The pancreatic cysts can cause compression and pain in CF patients, and may occa-
sionally need surgical therapy. 
Both in patients with and without steatorrhea exocrine pancreatic function, as determined 
by the NBT-PABA lest and the secretin-cholecystokinin test, was disturbed. The secretin-
cholecystokinin stimulation test in the CF patient without steatorrhea showed a moderately 
reduced pancreatic enzyme output, but a strongly reduced bicarbonate output. Steatorrhea 
does not seem to occur until the secretion of pancreatic lipase is approximately below 10 
% of normal, but many other factors appear to play a role such as lingual lipase activity 
and co-lipase deficiency (15,16). The finding of low duodenal bicarbonate output after 
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secretin stimulation indicates a discrepancy between acinar (enzymes) and ductular (fluid, 
bicarbonate, electrolytes) pancreatic function, not often seen in other forms of pancreatic 
insufficiency (2). The CF patients, regardless of their ability to produce adequate 
pancreatic enzyme output, have an abnormality of pancreatic fluid and bicarbonate secre-
tion related to the genetic defective chloride channel function (17,18). To determine this 
discrepancy between acinar and ductular function, both secretin and cholecytokinin 
stimulation are needed in pancreatic function testing. 
All CF patients had evidence of an impaired endocrine pancreatic function as reflected by 
a blunted insulin secretion and virtual absence of pancreatic polypeptide secretion in 
response to a standard meal. This finding is in agreement with a previous study in adult 
CF patients (19). PP-producing cells occur almost exclusively in the pancreas (20). 
Postprandial rise in plasma PP has been suggested to be a measure of functional pancrea-
tic mass in chronic pancreatitis, but in these patients the PP secretion remained normal 
until the pancreas was so damaged that the disease usually had revealed itself by overt 
steatorrhea (20). PP-cells are scattered in the exocrine parenchyma and in the islets where 
they are usually located at the periphery (20,21). In the present study basal and maximal 
plasma PP levels correlated well with the diameter of the pancreatic body suggesting that 
pancreatic atrophy is accompanied by a decrease in either the number or function of PP-
cells. Disruption of pancreatic architecture by fibrosis and fatty infiltration is probably 
responsible for the observed findings (13). A blunted, but still significant, insulin 
response to meal ingestion was found, irrespective of exocrine pancreatic function. 
Therefore, the results indicate that the insulin-producing cells, which are located in the 
islets, arc much less susceptible to the damaging process of the pancreas in CF than the 
PP-producing cells and the exocrine tissue. Nevertheless, the number of islets per mm3 
pancreatic tissue was found to be decreased in CF patients with and without diabetes (22). 
In addition, islet cell antibodies may play a role in the development of diabetes mellitus in 
CF (23). 
The sweat test is the cornerstone to diagnose CF, but the test can yield borderline results. 
Modification of the sweat test using fludrocortison can aid the diagnosis further (24), but 
normal sweat electrolyte levels may be found in patients with typical CF (23). In such 
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cases ancillary criteria for the diagnosis of CF have to be relied upon. The demonstration 
of characteristic features at ultrasound and at exocrine pancreatic function testing can 
support the diagnosis of CF. 
It is concluded that in adult CF patients ultrasonography demonstrates abnormalities in 
pancreatic morphology which are characterized by a large pancreatic head relative to a 
small and echodense body. Exocrine and endocrine pancreatic function are disturbed in all 
patients, irrespective of the presence of steatorrhea. These functional and morphological 
abnormalities can support the diagnosis of CF in case of borderline or negative sweat test 
results. 
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Summary 
In patients with cystic fibrosis, abnormalities in plasma cholecystokinin 
level and gallbladder emptying may contribute to the development of maldigestion and 
gallstones. Therefore, we have measured plasma cholecystokinin levels and gallbladder 
volumes before and after ingestion of a standard breakfast in eight adult patients with 
cystic fibrosis and in eight normal control subjects. In the patients with cystic fibrosis 
basal (2.8 ±_ 0.4 pmol/1; ρ < 0.05, t-test) and maximum post-prandial (5.7 ±, 0.5 pmol/1; 
ρ <0.05, t-test) plasma cholecystokinin levels were significantly higher than those in the 
control subjects (1.9 ±. 0.1 pmol/1, and 4.5 ±_ 0.2 pmol/1, respectively). On the other 
hand, integrated plasma cholecystokinin secretion in response to the meal was similar ( t-
test, ρ = 0.4 versus control subjects). The increased plasma cholecystokinin levels in the 
patients with cystic fibrosis were accompanied by reduced gallbladder volumes in both the 
basal (7.8 ±.2.1 cm3 versus 20.9 ± 2.3 cm3 in control subjects; ρ < 0.005, t-test) and 
the post-prandial state (2.2 ±_ 1.0 cm3 versus 4.8 ±_ 0.8 cm3 in control subjects; ρ = 
0.06, t-test). Gallbladder emptying in the patients with cystic fibrosis was well preserved 
(70% ±_ 7% versus 78% ±. 9% in control subjects; ρ = 0.4, t-test). In comparison with 
normal control subjects, patients with cystic fibrosis have an increased basal plasma 
cholecystokinin level and a reduced gallbladder volume, whereas post-prandial gallbladder 
emptying and plasma cholecystokinin secretion are not significantly different. In cystic 
fibrosis, neither impaired cholecystokinin release nor impaired gallbladder emptying 
appear to play a role in the pathogenesis of either gallstones or maldigestion. 
Introduction 
In patients with cystic fibrosis (CF), survival may be influenced by the nutritional 
implications of the exocrine pancreatic insufficiency present in 85% of patients (1). An 
impaired emptying from the gallbladder of bile acids, needed for emulsification and 
micellar solubilization of fatty nutrients in the proximal gut, may further aggravate 
malabsorption (2, 3). Plasma cholecystokinin is a major hormonal stimulus of pancreatic 
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enzyme secretion and gallbladder contraction (4-7). A diminished plasma cholecystokinin 
secretion and gallbladder contraction could not only affect fat digestion, but could also 
contribute to the formation of gallstones, another prominent feature in patients with CF 
(1,5). In fact, low plasma cholecystokinin levels and a reduction in gallbladder emptying 
have been described recently in patients with severe pancreatic insufficiency owing to 
chronic pancreatitis (8-10). The aim of the present study was to determine whether 
plasma cholecystokinin levels and gallbladder emptying are reduced in patients with CF. 
Plasma cholecystokinin levels and gallbladder volumes were measured in patients with CF 
and in normal control subjects before and after ingestion of a standard breakfast. 
Methods 
Eight adult patients (six male, two female; mean age 28 range 22-41) with CF were 
studied. CF was diagnosed by a positive sweat test and typical pulmonary and/or digestive 
symptoms. All patients had evidence of exocrine pancreatic dysfunction as reflected by a 
decreased urinary excretion of p-aminobenzoic acid (PABA) after oral administration of n-
benzoyl-1-tyrosyl-p-aminobenzoic acid (n-BT-PABA), and all but one patient had an 
increased faecal fat excretion (Table 6.1). Futhermore, destruction of pancreatic tissue 
was suggested in all patients, except patient no. 3, by the finding of low basal (range 6-16 
pmol/1; normal subjects: (mean ±, SD), 44 +. 10 pmol/1) and postprandial (range 13-35 
pmol/1; normal subjects > 40 pmol/1) plasma pancreatic polypeptide concentrations (11). 
In patient no. 3 pancreatic polypeptide levels were elevated, possibly due to an impaired 
renal function ( glomular filtration rate, 40 ml/min). This patient had insulin-dependent 
diabetes mellitus, indicating pancreatic involvement. Pancreatic enzyme therapy was 
withheld for 5 days before the investigation. In addition, eight normal control subjects 
(four male, four female; mean age 22 range 19-25) without known gastrointestinal or 
metabolic diseases were studied. Informed consent was obtained from all subjects and 
patients studied and the protocol was approved by the Ethics Committee of Nijmegen 
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PATIENT 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
Normal 
value 
AGE 
(years) 
27 
27 
25 
22 
22 
41 
33 
24 
SEX 
F 
M 
M 
M 
M 
F 
M 
M 
FAECAL FAT 
EXCRETION 
(g/24 h) 
1.9 
67.1 
39.2 
31.6 
27.4 
8.1 
42.0 
59.3 
< 7.0 
URINARY 
EXCRETION OF 
PABA (%) * 
31 
9 
25 
11 
10 
44 
10 
19 
> 50 
Table 6.1: Patient data. 
* Percentage of PABA equivalents recovered in 6 H after oral 
ingestion of 2 mmol of n-BT-PABA. 
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B a s a l p l a s m a CCK (pM) 
ρ < 0.05 
- B a s a l g a l l b l a d d e r -
volume (cm3) 
1-
25 
20 
15 
10 
ρ < O.OOS 
normal 
subjects 
(n = 8) 
CF 
patients 
Ιη = β) 
n o r m a l 
subjects 
(n = 8) 
».r 
patients 
(n = B) 
Figure 6.1 
Basal plasma CCK concentration (left panel) and basal gallbladder volume (right panel) in 
eight patients with CF (hatched bars) and eight control subjects (open bars). Values are 
means with bars indicating SEM. 
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University Hospital. 
After an overnight fast, the subjects, during a IS min period, ingested a standard breakfast 
consisting of 30 g of fat, 30 g of protein and 70 g of carbohydrate (one slice of white 
bread, 5 g of margarine, 50 g of cheese, 200 g of yoghurt with SO g of D-glucose, one 
soft-boiled egg and 150 ml of tea). Blood was drawn for cholecystokinin measurement 
before and at 15 min intervals until 90 min after start of the meal. Each time that a blood 
sample was drawn, two longitudinal and two transverse images of the gallbladder were 
obtained by real-time ultrasonography (12). Plasma cholecystokinin levels were measured 
by a sensitive and specific RIA using antibody T204 (13). The antibody binds to all C-
terminal cholecystokinin peptides containing the sulphated tyrosine region. The antibody 
shows less than 2% cross-reactivity with sulphated gastrins and does not bind to unsulpha-
ted forms of gastrin. It does not cross-react with structurally unrelated peptides, such as 
insulin, glucagon, secretin, pancreatic polypeptide, bombesin and neurotensin. One 
millilitre of the plasma samples was extracted by adding 2 ml of 96% (v/v) ethanol. After 
mixing and centrifugation, the supernatant was evaporated to dryness under nitrogen at 
37nC. The dried supernatant was reconstituted in assay buffer to the original sample 
volume. The detection limit of the assay was between 0.5 and 1.0 pmol/l of plasma. All 
plasma samples were measured in the same cholecystokinin assy. The intra-assay variation 
ranged from 4.6 to 11.5%. Gallbladder volume was calculated by the sum of cylinders 
method using a computer system (12). The variation of volume measurements ranged 
from 6.0 to 22.4%. Both plasma cholecystokinin levels and gallbladder volumes were 
measured in duplicate and the mean of two measurements was used for further analysis of 
results. 
Results were expressed as mean ±_ SEM. Integrated plasma cholecystokinin secretion was 
determined by calculating the area under the plasma concentration-time curve after 
substraction of the basal value. Integrated gallbladder emptying was determined by 
calculating the area under the gallbladder emptying-time curve. Residual gallbladder 
volume in the individual patient was defined as the gallbladder volume after maximal 
emptying. Statistical analysis of the results was carried out by analysis of covariance and 
by Student's t-test for paired and unpaired data. Correlation coefficients were calculated 
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by linear regression analysis. 
Plasma CCK (pM) 
6-
3-
30 60 90 
Time (min) 
Figure 6.2 
Plasma CCK concentration in eight patients with CF (closed circles) and in eight control 
subjects (open circles) before and after ingestion of a standard meal. Asterisks denote 
significant differences between patients with CF and control subjects. Values are means 
with bars indicating SEM. 
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Gallbladder volume (cm'l 
20 
15-
10 
30 60 90 
Time (min) 
Figure 6.3 
Gallbladder volumes in eight patients with CF (closed circles) and in eight control subjects 
(open circles) before and after ingestion of a standard meal. Asterisks denote significant 
differences between patients with CF and control subjects. Values are means with bars 
indicating SEM. 
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In the patients with CF, the basal plasma cholecystokinin concentration (2.8 ±_ 0.4 
pmol/1) was significantly (p < 0.05, t-test) higher than in the control subjects (1.9 ±_ 0.1 
pmol/1; Fig. 6.1A). In the control subjects the standard breakfast evoked an immediate 
and statistically significant increase in the plasma cholecystokinin concentration to a 
maximum value of 3.8 ±_ 0.3 pmol/1 at 75 min (ρ = 0.001, analysis of covariance; Fig. 
6.2). 
In the patients with CF a more gradual post-prandial increase in the plasma cholecystoki­
nin concentration to a peak value of 5.3 +. 0.4 pmol/1 at 90 min was observed ( ρ = 
0.003 analysis of covariance; Fig. 6.2). The individual peak cholecystokinin level in 
patients with CF was significantly higher than that in the control subjects (5.7 ±_ 0.5 
pmol/1 versus 4.5 ± 0.2 pmol/1; ρ < 0.05, t-test). At 45, 60, 75 and 90 min the post­
prandial plasma cholecystokinin concentration in the patients with CF were significantly (p 
< 0.005 to ρ < 0.05, t-test) higher than in the control subjects (Fig. 6.2). However, the 
peak cholecystokinin increment in the patients with CF (2.9 ±. 0.4 pmol/1) was compara­
ble with that in the control subjects (2.6 ±_ 0.3 pmol/1; ρ = 0.4, t-test). Similary, 
integrated plasma cholecystokinin secretion was not significantly different in the patients 
with CF (168 ± 28 pmol/1.90 min) and the control subjects (137 ± 17 pmol/1.90min; ρ 
= 0.4, t-test). 
The basal gallbladder volume in the patients with CF (7.8 ±_ 2.1 cm3; range 1.0-18.4 
cm
3) was significantly (p < 0.005, t-test) smaller than in the control subjects (20.9 ±_ 2.3 
cm
3; range 14.9-36.1 cm3; Fig. 6. IB). Ingestion of the meal induced a significant decrease 
in the gallbladder volume, both in the patients with CF (p = 0.001, analysis of covarian­
ce) and in the control subjects (p = 0.0001, analysis of covariance). In the patients with 
CF at 15, 45 and 75 min, the post-prandial gallbladder volume was significantly (p < 
0.05 to ρ < 0.001, t-test) smaller than in the control subjects (Fig. 6.3). Similarly, the 
residual gallbladder volume in the patients with CF (2.2 ¿ .1 .0 cm3) was smaller than in 
the control subjects (4.8 +_ 0.8 cm3; ρ = 0.06, t-test). The maximal decrease in gallblad­
der volume was significantly (p < 0.001, t-test) smaller in the patients with CF (5.6 ±_ 
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1.6 cm3) than in the control subjects (16.2 +_ 1.9 cm3). Similary, the integrated gallblad­
der emptying was significantly (p < 0.001, t-test) reduced in the patients with CF (308 ±_ 
110 cm3.90 min) when compared with the control subjects (1046 ±_ 164 cm3.90 min). 
However, when the gallbladder response was expressed as percentage of basal volume, 
maximal emptying in the patients with CF (70 ±_ 7%) was similar to that in the control 
subjects (78 ±. 9%; ρ = 0.4, t-test; Fig. 6.3). 
In the control subjects there was a significant correlation between plasma cholecystokinin 
concentration and gallbladder volume (r = -0.8354, ρ < 0.05, t-test). In the patients with 
CF there was an even stronger correlation (r = -0.9353, ρ < 0.005, t-test) between 
plasma cholecystokinin concentration and gallbladder volume. In two patients with CF 
(no. 6 and no. 8) gallstones were noted. In these two patients, basal and post-prandial 
plasma cholecystokinin concentrations, as well as gallbladder volumes in the basal and 
postprandial state, were not apparently different from those in the other patients with CF. 
Discussion 
Explanations for the higher basal and postprandial plasma cholecystokinin levels in 
patients with CF are speculative. All our patients with CF suffered from exocrine 
pancreatic dysfunction. Theoretically, it is possible that the increased plasma cholecystoki­
nin levels resulted from a diminished feedback inhibition by intraluminal proteases. 
Although such a mechanism probably exists in rats (4, 14), feedback inhibition of plasma 
cholecystokinin by pancreatic enzymes is still a matter of considerable controversy in man 
(4, 8-10, 15, 16). In patients with varying degrees of pancreatic insufficiency, due in 
general to chronic pancreatitis, conflicting results on plasma cholecystokinin levels have 
been reported (8-10, 15-17). Differences in the characteristics of patients studied, but 
especially in the assay conditions for cholecystokinin, may have accounted for these 
different findings. Recently, using carefully validated cholecystokinin assays, several 
investigators not only observed normal or low basal plasma cholecystokinin levels (8-10), 
but also a reduction in postprandial cholecystokinin secretion in patients with severe 
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pancreatic insufficiency due to chronic pancrctitis (8, 9). The contrasting findings in 
pancreatic insufficiency due to chronic pancreatitis and CF suggests that the elevated 
cholecystokinin levels in CF do not result from diminished intraluminal pancreatic enzyme 
activity, but are probably related to other factors. Another possible explanation for the 
increased plasma cholecystokinin levels in patients with CF is a diminished feedback 
inhibition of cholecystokinin producing cells by intraluminal bile salts. Convincing 
evidence has been presented that plasma cholecystokinin levels in man are inversely 
related to the presence of luminal bile salts (18, 19). It seems reasonable to argue that a 
small bile-acid poole size (20) and a reduction of bile-acid output into the duodenum (3) 
contributes, at least in part, to the increased plasma cholecystokinin levels before and after 
ingestion of a meal in patients with CF. 
Real-time ultrasonography is a carefully validated technique for the non-invasive quantifi-
cation of gallbladder emptying responses to physiologic stimuli in man (5, 12, 21, 22). 
Several characteristics of gallbladder emptying can be determined including the rate 
constant, half-time and overall percentage of emptying (5). Sonographically measured 
changes in gallbladder volume reflect gallbladder emptying as measured by means of 
cumulative intraduodenal bilirubin output in a close linear relationship (21). Moreover, the 
decreases in gallbladder volume measured with ultrasound are nearly identical with the 
decreases in gallbladder content as determined by cholescintigraphy (22). Ultrasonography 
cannot detect diversion of hepatic bile into the gallbladder when this storage process 
alternates at short intervals with ejection of bile from the gallbladder (23). Although the 
existence of such short-lived episodes of emptying and refilling in the postprandial period 
was recently suggested (23), this "bellows" effect is probably of minor importance in the 
delivery of bile into the duodenum, since that same study and other studies provide strong 
evidence that the secretion of bile into the duodenum results mainly from a more 
prolongated gallbladder contraction, inducing evacuation of bile stored in the gallbladder 
over a longer period of time (5, 21-23). 
Cholelithiasis is a frequent complication of CF, particularly in adult patients (24-26). 
Reported incidences vary between 6 and 30%. The high incidence of gallstones and the 
finding of a reduced duodenal total bile-acid output may reflect a defect in gallbladder 
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emptying in response to endogenous cholecystokinin (3, 5). In the present study, however, 
it was demonstrated that percentage emptying of the gallbladder was well preserved in the 
patients with CF. Basal gallbladder volume was significantly smaller in patients with CF 
than in normal subjects, but gallbladder volume decreased significantly after stimulation 
with a test meal. Residual volume after ingestion of a meal tended to be lower than that in 
normal subjects. The results of the present study, therefore, do not support the hypothesis 
that an impaired gallbladder emptying contributes to the formation of gallstones or 
maldigestion and malabsorption of dietary fat in CF. On the other hand, small gallbladder 
volumes may compromise storage of bile acids in the gallbladder (2), and thereby 
contribute to the smaller bile acid pool and reduced total bile acid output into the 
duodenum observed in CF (3, 20). 
The smaller gallbladder volumes in CF may have resulted from primary hypoplasia of the 
gallbladder or morphological changes of the gallbladder wall, including mucous hyperpla-
sia and shrinkage secondary to inflammation (24, 27). However, it seems more likely that 
volume reduction resulted from the increased plasma concentration of cholecystokinin, 
which is a major factor in the regulation of gallbladder volume in the basal state and after 
ingestion of a meal (5, 6, 28). The observation of an excellent correlation between plasma 
cholecystokinin levels and gallbladder volumes supports this hypothesis. Diminished basal 
and postprandial plasma levels of pancreatic polypeptide, which has an effect on the 
gallbladder that is opposite to that of cholecystokinin (5, 29), may have further augmented 
the contractile effect of cholecystokinin. Theoretical implications of the increased plasma 
cholecystokinin levels in CF may be a reduction of lower oesophagal sphincter pressure 
facilitating gastro-oesophagal reflux and inhibition of gastric emptying. 
In conclusion, in patients with CF increased basal and postprandial plasma cholecystokinin 
levels are accompanied by reduced basal and postprandial gallbladder volumes. Post· 
prandial gallbladder emptying and plasma cholecystokinin secretion are well preserved. In 
CF, neither impaired cholecystokinin release nor impaired gallbladder emptying appear to 
play a role in the pathogenesis of either gallstones or maldigestion. 
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Summary 
Spirometry, body plethysmography, MEFV-curves with air and with heliox before and 
after inhalation of bronchodilators were studied in a group of 20 adult cystic fibrosis 
patients. Most of them showed prominent bronchial obstruction and 7 had also evidence of 
restrictive pulmonary disease. Great differences were observed between total lung capacity 
as measured with bodyplethysmography and with a helium dilution technique. A calcula-
ted airtrapping index correlated well with parameters of peripheral airway obstruction. 
Both inhalation of terbutaline and ipratropium bromide caused dose-related bronchodilata-
tion. Fourteen patients showed a more than 15 % increase in FEV-1 after one or both of 
the bronchodilators. Density dependence of expiratory flow increased significantly after 
terbutaline but not after ipratropium bromide. 
We conclude that adult CF patients with varying degrees of obstructive and restrictive 
pulmonary function limitation show a dose-related improvement of lung function after 
terbutaline and ipratropium bromide with terbutaline being probably more effective on 
peripheral airways than ipratropium bromide. 
Keywords: 
Cystic Fibrosis, Terbutaline, Ipratropium bromide, Bronchodilator response, Density 
dependence. 
Introduction 
The reported prevalence of bronchodilator responsiveness in children with cystic fibrosis 
(CF) varies from 0-43 % in cross-sectional studies with mean ages of studied patients 
below 18 years (1-3).Some patients even demonstrated a reduction in airflow after inhaled 
isoproterenol (2). End-expiratory flow rates appeared to be the most accurate parameters 
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in reflecting the bronchodilator response in CF patients (4).When breathing a low-density 
gas mixture like heliox (80 % helium and 20 % oxygen) the density dependence expressed 
as delta MEF-50 can be assessed. A delta MEF-50 of < 20 % is compatible with 
obstruction in peripheral airways (5-8). When a bronchodilator predominantly dilates 
small airways, the central turbulent airflow pattern will contribute more lo overall 
resistance and delta MEF-50 increases. Effects of Beta-adrenoreceplor agonists and 
muscarinic receptor antagonists on large and small airways have been determined in 
normal subjects and patients with asthma by assessing this density dependence (6,9-11). 
The aim of the present study was to investigate the difference in bronchodilator effect 
between the Beta-adrenoreceptor agonist terbutaline and the muscarinic receptor antagonist 
ipratropium bromide with regard to magnitude and preferential site of action in adult CF 
patients. The effects of two different doses of terbutaline and ipratropium bromide were 
measured on lung function and density dependence of expiratory flow in a group of 20 
adult patients with CF. 
Subjects and methods 
Twenty patients (13 M, 7F; 18-43 years of age, mean age 26) with CF participated in the 
study. They represented a wide variety in clinical severity (range FEV-1 % predicted: 
15,6- 107,6 %) and all were experienced in performing pulmonary function tests. None of 
the patients was treated with corticosteroids, theophylline or sodium cromoglycate. 
Bronchodilators were withheld fore at least 12 hours prior to each study. Baseline 
spirometrie measurements, including total lung capacity measurement with a closed circuit 
helium dilution method (TLC-helium), were obtained with a wet spirometer (Pulmonet 
III,Sensor Medics,Bilthoven.The Netherlands). A constant volume body Plethysmograph 
(Jaeger Bodyscreen II, Wuerzburg, Federal Republic of Germany) was used to measure 
the airway resistance ( Raw ), the residual volume ( RV ), the thoracic gas volume ( TGV 
), total lung capacity (TLC-box) and the specific airway conductance (SGaw) (12). For 
calculations a modified "airtrapping" index ( AT-index ) was defined as follows: "AT-
index" = (TLC-box) - (TLC-helium) S (TLC-helium) χ 100 % (20, 21). Five technically 
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satisfactory Plethysmographie determinations were obtained and averaged. Measurements 
were expressed in percent of predicted values (13). A restrictive pattern of pulmonary 
disease was defined by the following criteria: (1) vital capacity (VC) less than or equal to 
75 percent of predicted and (2) TLC less than or equal to 80 percent of predicted (14). 
Maximal expiratory flow-volume curves (MEFV curves) were obtained with a Jaeger 
Pncumoscreen (Jaeger,Wuerzburg,Federal Republic of Germany). All the subjects 
performed two series of MEFV curves with air and two with He-02. Before each set of 
measurements, the flow-volume equipment was calibrated separately with room air and 
the He-02 mixture. Ventilatory parameters were taken from the composite curve with the 
highest sum of FVC and FEV-1. The composite curve was obtained by taking the 
"envelope" of a serie of three individual curves superimposed at TLC level (15). The HE-
02 MEFV curves with the best fitting FVC's compared to the air MEFV curves were 
used for calculation. The He-02 mixture was washed in during 1 minute tidal breathing in 
wich the patient was asked to inhale three slow vital capacities (9,11). Density dependence 
was expressed as delta- MEF-50 = {MEF-50 ( He-02 ) - MEF-50 ( AIR )} / MEF-50 ( 
AIR ) χ 100 % (6). 
Bronchodilator effects were investigated on two different days in randomized order with 7 
days between the two days of investigation. The difference in baseline FEV-1 ( MEFV-
curves) on the two days was < 5 %. MEFV curves with air and He-02 were obtained 
before, and 20 minutes after inhalation of 1 and 2 mg terbutaline cumulatively at the first 
day, and before and 40 minutes after inhalation of 40 and 80 ug ipratropium bromide 
cumulatively at the other day. The doses of the two drugs were selected on account of 
previous dose-response studies in asthmatic patients. Both bronchodilators were inhaled 
as pressurized aerosol through a 750 ml spacer (Nebuhaler R) to ensure proper deposition 
in the airways. The study protocol was approved by the local ethics committee and 
informed consent was obtained from all patients before entry into the study. For statistical 
calculations, analysis of variance with repeated measures (ANOVA), Mann-Whitney U 
tests and Spearman's rank correlation coefficients were used as appropriate. Five percent 
was taken as the level of significance. 
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PT AGE FEV-1 MEF- MEF- TLC- VC AT- RV/ sGaw FEV-1/ 
no yr %pred 50 25 Не %pred index TLC %pred VC 
%prcd %pred %pred % % % 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
19 
22 
24 
27 
43 
24 
26 
23 
43 
26 
20 
29 
18 
25 
18 
35 
18 
19 
29 
29 
43 
41 
67 
96 
24 
16 
55 
46 
67 
31 
75 
95 
45 
40 
108 
61 
70 
42 
70 
10 
16 
21 
39 
73 
9 
7 
28 
18 
43 
11 
60 
74 
18 
17 
82 
30 
'57 
21 
57 
7 
7 
14 
19 
51 
10 
7 
20 
13 
40 
8 
30 
31 
14 
15 
53 
22 
46 
13 
31 
77 
78 
78 
90 
107 
61 
54 
94 
74 
90 
82 
89 
105 
91 
86 
115 
86 
88 
76 
103 
66 
73 
68 
82 
108 
46 
42 
81 
67 
90 
66 
87 
107 
80 
65 
119 
91 
78 
65 
110 
30 
15 
28 
13 
0 
47 
57 
22 
21 
17 
29 
10 
3 
23 
10 
7 
10 
7 
15 
7 
50 
33 
53 
37 
8 
73 
75 
44 
47 
42 
53 
29 
25 
42 
49 
15 
33 
27 
34 
29 
27 
96 
18 
81 
204 
17 
53 
53 
60 
46 
31 
106 
179 
38 
72 
128 
85 
145 
58 
86 
36 
50 
53 
66 
72 
44 
31 
54 
54 
62 
40 
75 
72 
48 
51 
74 
53 
73 
53 
55 
mean 26 55 35 22 86 80 19 40 79 56 
±sem 2 6 5 3 3 5 3 4 12 3 
Table 7.1 : Patient characterics and baseline results of spirometry and 
bodyplethysmography in 20 adult patients with CF. 
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FEV-1 MEF-50 MEF-25 AT-index RV/TLC sGaw 
%pred %pred %pred % % %pred 
MEF-50 0.97 
%pred *•• 
MEF-25 0.89 0.93 
%pred *** »•* 
AT-index 
% 
RV/TLC 
% 
sGaw 
%pred 
increase 
FEV-1(T) 
-0.85 
-0.91 
*** 
0.83 
-0.61 
** 
-0.84 
*** 
-0.88 
»** 
0.77 
** 
-0.58 
* 
-0.79 
* » + 
-0.79 
** 
0.68 
** 
-0.50 
* 
0.91 
*** 
-0.92 
*** 
0.60 
* + 
-0.90 
*** 
0.59 
* 
-0.70 
*# 
Table 7.2: Correlation of ventilatory parameters in 20 adult patients with CF, 
expressed in Spearman's rank correlation coefficients. 
Increase FEV-1 (T) = % increase in FEV-1 after inhalation of 2 mg 
terbutaline. 
* ρ < 0.05; ** ρ < 0.01: ·** ρ < 0.001. 
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Results 
Baseline lung function showed bronchus obstruction in 13 patients, whereas seven patients 
(no 1,2,3,6,7,9,19) had a combined obstructive and restrictive lung function pattern 
(Table 7.1). Three patients (no 5,13,16) had only a lowered MEF-25 (%pred) or no 
functional abnormalities. In several patients a marked difference was found between 
TLC-box and TLC-helium. When expressed as a ratio, the mean "airtrapping index" was 
18.5 N 3.2 % (range 0-56 %). This AT-index was significantly correlated with other 
parameters of airway obstruction (Table 7.2). The AT-index appeared to be greater with 
decreasing values of sGaw, FEV-1, MEF-50 and MEF-25 and with increasing values of 
RV/TLC (Figure 7.1, Table 7.2). 
Inhalation of both terbutaline (T) and ipratropium bromide (IB) induced significant, dose-
related bronchodilatation (Figures 7.2 and 7.3). The FEV-1 increased from 55.9 ±_ 5.6 % 
predicted (mean ± sem) to 62.5 ± 5.7 % after 2 mg Τ and to 66.0 ± 6.1 % after 80 
meg IB. The MEF-25 increased from 22.4 ± 3.4 % to 27.7 ± 4.5 % after 2 mg Τ and 
to 31.2 +. 5.2 % after 80 meg IB. There was no significant difference (analysis of 
variance for repeated measures) between the magnitude of bronchodilatation induced by 
Τ or IB. Considering a more than 15 % increase in FEV-1 above baseline values as 
clinically relevant, 9 patients showed such a response to T, and 11 patients to IB. A total 
number of 14 of the 20 patients showed a clinically relevant response to one or both of 
the bronchodilators. The increase in FEV-1 after Τ was significantly correlated with 
baseline lung function (Table 7.2). The response to IB was not determined on the same 
day as baseline lung function, so a correlation was not investigated here. 
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Baseline values of density dependence, expressed as delta MEF-50, showed that 16 of the 
20 CF patients were "nonresponders" for heliox ( delta MEF-50 < 20 % ). The FEV-1 
and MEF-25 of the "responders" (79.5 ± 14.0 % and 37.3 ± 18.3 % predicted; mean 
±_ sem) were significantly higher (p < 0.05; Mann-Whitney U test) than the FEV-1 and 
MEF-25 of the "nonresponders" (50.1 ± 5.3 % and 18.7 ± 3.0 % respectively). 
Terbutaline caused a significant increase in delta MEF-50 and 8 of the 16 "nonrespon-
ders" became "responders" after 2 mg terbutalinc. Ipratropium bromide had no significant 
effect on delta MEF 50 (Figures 7.4 and 7.5). 
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Airtrapping index (%) 
100-
50 
10-
π 1 1 1 1 Γ 
40 80 120 
FEV, (% predicted) 
Figure 7.1 
Correlation between airtrapping index and baseline FEV-1 (% predicted) in 
20 adult CF patients. Log expression of AT-index is used. 
Ryx =-0.83; ρ = 0.0008. 
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% predicted 
Omg terbutaline 1mg terbutahne 2mg terbutaline 
Figure 7.2 
Changes (mean ±_ sem) in ventilatory parameters as a percentage of baseline values after 
inhalation of cumulative doses of terbutaline in 20 adult patients with CF. Asterisks 
indicate a significant difference when compared with baseline values (analysis of variance 
for repeated measures). * ρ < 0.001; ** ρ < 0.05. 
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% predicted 
Omcg ipratropium 1,0 meg ipratropium 80mcg ipratropium 
bromide bromide bromide 
Figure 7.3 
Changes (mean ±. sem) in ventilatory parameters as a percentage of baseline 
values after inhalation of cumulative doses of ipratropium bromide in 20 
adult patients with CF. Asterisks indicate a significant difference when compared with 
baseline values (analysis of variance for repeated measures). 
* ρ < 0.001; •* ρ < 0.01. 
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Figure 7.4 
Effects of different doses terbutaline on density dependence expressed as 
delta MEF-50 (mean ±_ sem) in 20 adult patients with CF. Asterisks indicate 
a significant difference when compared with baseline values (analysis of 
variance for repeated measures). * ρ < 0.001. 
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Figure 7.5 
Effects of different doses ipratropium bromide on density dependence expressed as delta 
MEF-50 (mean ±_ sem) in 20 adult patients with CF. Asterisks indicate a significant diffe­
rence when compared with baseline values (analysis of variance for repeated measures). * 
ρ < 0.001. 
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Discussion 
Obstructive pulmonary function limitations are common in patients with CF (16) and 
many patients also have evidence of restricted pulmonary function. In the present study 7 
of 20 adult CF patients showed restricted pulmonary function but it is uncertain whether 
restriction indicates more severe disease in CF patients (14). 
Specific airway conductance (sGaw) and airway resistance (Raw) are usually normal in 
children with CF and mild pulmonary involvement, presumably because small airways are 
responsible for only 10-20 % of total airway resistance (18,19). In the present study, 
markedly decreased values of sGaw were found in adult CF patients with severe 
obstructive lung disease. sGaw values correlated well with other ventilatory parameters 
(Table 2) and reflected either extensive small airway obstruction or large airway involve-
ment or both. 
Obstruction of small airways leads to poor ventilation of certain areas of the lung. The 
resulting airtrapping and hyperinflation is reflected by a large RV / TLC ratio and a large 
trapped-gas volume: i.e. the difference between TLC-box and TLC-helium (20). In 
children with CF an increased ratio of RV / TLC was mainly due to airtrapping and to a 
lesser extent to decreased elastic lung recoil (22). It seems to be an early and consistent 
abnormality, correlated to clinical severity of the disease (23). In asthmatic patients with 
significant airflow obstruction, TLC-box seems to overestimate the true total lung capacity 
(23,24). The magnitude of ovcrestimation depends probably on the distensibility of 
extrathoracic airways and the degree of small airway obstruction, especially in severe 
cases. Even if this does explain the changes in measurement of TLC-box, this artefact still 
remains a function of the degree of airway obstruction and the determination of the air-
trapping index has relevance in the assessment of these patients (20,21). In this study the 
airtrapping-index correlated significantly with RV/TLC, MEF-50 and MEF-25 and 
probably represents airtrapping due to peripheral airway obstruction. A 
significant, dose related, bronchodilatation after both terbutaline and ipratropium bromide 
was found in the adult CF patients. The bronchodilator effects were reflected by increases 
in FEV-1, MEF-SO and MEF-25 values. Six of the 20 patients did not respond to either 
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bronchodilator. A clinically relevant bronchodilator response, defined as a more than 15 
% increase in FEV-1, was found in 70 % of the adult CF patients. In contrast to Zach et 
al. (4) who observed impairment of lung function in some children with CF, we did not 
observe any negative responses to bronchodilator therapy. In adults, bronchodilator 
responsiveness therefore appears to be more common than in children with CF where a O-
43 % prevalence in cross-sectional studies was observed (1-4). In contrast to most earlier 
studies we used two different doses of two bronchodilator drugs and performed flow-
volume curves instead of spirometry, which has been reported to be less sensitive to 
assess bronchodilator responsiveness in CF patients (4). Another explanation for the 
observed difference might be that bronchodilator responsiveness is more prevalent in 
adults when compared to children with CF , but this remains to be proved. 
Most of the adult CF patients were nonresponders for heliox (delta MEF-50 < 20 %) 
compatible with predominant peripheral airway obstruction. The CF patients who were 
responders (delta MEF-SO > 20 %) had significantly better pulmonary function tests 
than nonresponders, also indicating the important contribution of small airways obstructi-
on to airflow limitation in CF. 
Several authors found different localizations of the effects of bronchodilators on normal 
subjects and patients with asthma (6,9-11). The most consistent finding was that beta-
sympathicomimetics predominantly cause dilatation of small airways, especially when 
these contribute to a large extent to total airway resistance (6,10,11). In the present study 
terbutaline induced a significant and consistent increase in density dependence in adult CF 
patients. Therefore it seems that terbutaline mainly caused dilatation of the peripheral 
airways, whereas ipratropium bromide presumably dilates large and small airways 
equally, leaving density dependence relatively unchanged (6). 
In conclusion, adult CF patients usually have mild to severe bronchus obstruction, 
especially of small airways. Moreover, many of this patients also have a restricted lung 
function pattern. Terbutaline and ipratropium bromide caused a dose-related bronchodila-
tation, terbutaline being probably more effective on small airways than ipratropium 
bromide. Longitudinal studies are needed for further evaluation of the potential beneficial 
effects of bronchodilator drugs on lung function and life expectance of CF patients. 
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Summary 
Atopy and bronchial responsiveness to histamine, exercise, and bronchodilators were 
investigated in eighteen adult patients with cystic fibrosis (CF). Reversibility of airflow 
limitation was measured after ipratropium bromide and terbutaline, and histamine and 
exercise provocation tests were performed. Histamine hyperresponsiveness was observed 
in 10 of 18 patients and was not confined to those with severe airway obstruction. The 
positive histamine responders showed significantly better bronchodilatation after terbutali-
ne when compared to negative histamine responders. Histamine responsiveness was not 
related to atopy or exercise responsiveness. Exercise challenge caused bronchodilatation 
without bronchoconstriction in all patients. The exercise-induced bronchodilatalion 
correlated with bronchodilatation after ipratropium bromide. It is suggested that an 
increased vagal tone may lead to an increased resting bronchomotor tone which can be 
reduced by ipratropium bromide and by exercise in adult patients with cystic fibrosis. 
Keywords: 
Bronchial hyperresponsiveness, cystic fibrosis, exercise test, histamine provocation test, 
terbutaline, ipratropium bromide, atopy, vagal lone. 
Introduction 
The reported prevalence of bronchodilator responsiveness in children with cystic 
fibrosis (CF) varies from 0-43 % in cross-sectional studies (1-4). Bronchial hyperrespon-
siveness (BHR), as measured by bronchial inhalation provocation tests with histamine or 
methacholine, is present in 24-51 % of children with CF (4-8). A bronchoconstrictor or 
bronchodilator response to exercise challenge has been documented in 22-58 % of 
children with CF (9-13). Positive skin tests to inhalational allergens have been reported in 
48-88 % of children with CF (4,9,10). 
For optimal treatment it seems relevant to determine the significance of these pheno-
mena also in adult patients with CF. The mean age of patients in previous studies on this 
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subject was below 18 years. The purpose of this study therefore was to investigate the 
presence of bronchial responsiveness to inhaled histamine, exercise and bronchodilators 
and atopy in adult patients with CF. 
Methods 
Subjects 
All patients from our adult cystic fibrosis clinic were examined to enter the study. 
Exclusion criteria were: age < 18 years; a recent ( < 6 weeks) pulmonary exacerbation; 
FEV-1 < 25 % predicted (15); respiratory insufficiency. Eighteen CF patients (12 M, 6 
F; 18-43 years; mean age 25; Table 8.1) participated in the study. They represented a 
wide variety in clinical severity. None of the patients was treated with corticosteroids, 
theophylline or sodium cromoglycatc. All patients were questioned about a history of 
wheezing, bronchodilator use and family history of atopy and/or asthma. Bronchodilators 
were omitted for at least 12 hours before each study. The study protocol was approved by 
the institutional ethic's committee and informed consent was obtained from each patient. 
Bronchodilator responsiveness 
Reversibility of airflow limitation was measured by obtaining ventilatory parameters 
before and 40 minutes after inhalation of 80 meg ipratropium bromide (IB) and, on a 
separate day, before and 20 minutes after inhalation of 2 mg terbutaline (T) through a 
spacer device (table 8.2). All ventilatory parameters were measured with flow-volume 
equipment (Pneumoscreen, Jaeger, FRG). Several components of airflow rate and exhaled 
lung volumes were assessed with the so-called "envelope method": the indices were read 
on the composite curve, obtained by taking the envelope of three individual curves 
superimposed at TLC level (14). Results were compared with predicted values for height 
and age (15). 
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PATIENT SEX AGE HEIGHT WEIGHT 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
И 
12 
13 
14 
15 
16 
17 
18 
MEAN 
SEM 
M 
M 
F 
M 
M 
M 
M 
F 
F 
F 
M 
F 
M 
M 
M 
M 
M 
F 
(yr) 
21 
19 
22 
24 
27 
26 
23 
43 
26 
20 
29 
18 
25 
18 
35 
18 
19 
29 
25 
2 
(cm) 
169 
166 
178 
181 
172 
179 
185 
165 
164 
163 
174 
166 
167 
179 
174 
185 
174 
172 
173 
2 
(kg) 
47 
54 
63 
64 
66 
72 
61 
60 
47 
53 
66 
53 
57 
63 
77 
61 
51 
67 
60 
2 
Table 8.1: Anthropometric data of 18 adult cystic fibrosis patients. 
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Bronchial provocation tests 
In random order, on two different days with seven days between the two tests, we 
performed histamine inhalation challenges and exercise tests. Histamine provocation was 
performed according to the method of Cockcroft (16) with twofold increasing concentrati-
ons of histamine from 0.03 to 16 mg/ml. After reaching a > 20 % fall in FEV-1, a 
computerized calculation of PC-20 histamine was made. 
Standardized exercise provocation tests were performed by running on a treadmill in a 
room with constant temperature (20 degree C) and relative humidity (60 %) (17). After 
adaptation to the treadmill for 2 minutes at a speed of 4-6 km/hr, the slope and speed 
were raised until the heart rate reached 90 % or more of the age-related predicted 
maximum (18). At this level the exercise continued for 6 minutes. All patients reached 
90 % of their age-related predicted maximum heart rates. A nose clip ensured mouth 
breathing during the exercise performance. Pulmonary function tests were performed 
before, immediately after, and 1,3,6,9,12 and 15 minutes after completion of the exercise 
tests. The largest rises and falls in FEV-1, expressed as % rise or % fall of baseline FEV-
1, were calculated. A more than 15 % fall or 15 % rise in FEV-1 was considered as a 
positive response to exercise (19). 
Atopy 
Blood was collected to detect specific IgE antibodies to 10 common inhalational 
allergens (house dust, aspergillus f um., dog hair, cat fur, D. pteronyssinus, tree pollen 
and four mixes of grass pollen) using a standard RAST method (20). Atopy was 
considered as at least one positive test result by the RAST method (21). 
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Statistics 
For statistical analysis t-tests for paired and unpaired data and Pearson correlation 
coefficients were used. Five percent was taken as the level of significance. All data are 
presented as means ±_ SEM. 
Results 
The individual data for FEV-1 before and after terbutaline, ipratropium bromide and 
exercise are given in Table 8.2, together with the PC-20 to histamine. Data with respect 
to the histamine responders and non-responders are given in Table 8.3. The family 
histories did not reveal atopy or asthma in this group. One patient reported wheezing and 
five patients regularly used bronchodilators. Bronchodilator responses were measured on 
two separate days and baseline lung function did not differ between the two days. 
PT FEV-1 FEV-1 FEV-1 FEV-1 FEV-1 FEV-1 FEV-1 FEV-1 FEV- PC-20 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
% 
PRED 
BE­
FORE 
Τ 
29 
43 
41 
67 
96 
55 
46 
67 
31 
75 
95 
45 
40 
108 
61 
70 
42 
70 
% 
PRED 
AF­
TER 
Τ 
34 
51 
49 
73 
109 
67 
51 
78 
38 
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11 
10 
10 
17 
% 
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37 
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43 
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36 
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45 
45 
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71 
74 
44 
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% 
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AF­
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53 
53 
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74 
38 
82 
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53 
53 
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83 
84 
50 
82 
1 
% b 
AF­
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7 
7 
43 
8 
3 
23 
10 
5 
7 
7 
13 
19 
17 
8 
16 
13 
13 
14 
hista­
mine 
mg/ml 
> 16 
1.38 
> 16 
> 16 
1.82 
5.35 
0.49 
3.23 
0.27 
> 16 
3.68 
0.99 
1.72 
> 16 
> 16 
> 16 
> 16 
3.80 
M 60 67 15 61 71 18 63 71 13 
EA 
N 
S E 5 5 2 5 6 3 6 6 2 
M 
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Table 8.2: Ventilatory parameters before and after inhalation of 2 mg terbutaline (T) and 
80 meg ipratropium bromide (IB) and before and immediately after exercise 
(EXE) in 18 adult CF patients. 
101 
HISTAMINE HISTAMINE Ρ 
RESPONDERS NONRESPONDERS 
Patients (η) 
Male / Female 
Age yrs 
FEV-1 (% pred) 
VC (% pred) 
% rise in FEV-1 after 
terbutaline 
ipratropiumbromide 
% rise in FEV-1 immediately 
after exercise 12 ± 2 15 ± 4 NS 
% fall in FEV-1 after exercise 1 ± 0.4 _ 1 ± 1.0 NS 
Atopie subjects 6 3 NS 
Table 8.3: Baseline lung function, bronchodilator response and response to 
exercise in 18 adult CF patients. Comparison of positive 
histamine responders and negative histamine responders. Results 
are expressed as mean +. sem. NS = not significant. 
Inhalation of both terbutaline and ipratropium bromide significantly improved expiratory 
airflow. When expressed as per cent change from baseline, mean FEV-1 increased 14.5 
±_ 2.0 % after terbutaline and 17.6 ±_ 2.9 % after ipratropium bromide. 
Ten patients showed a positive response to histamine inhalation (i.e. PC 20 < 8 mg/ml). 
In these ten patients there was no correlation between the log PC 20-histamine and 
baseline FEV-1 expressed as per cent predicted (r=0.5; p>0.1). The eight patients with a 
negative response to histamine were not included in this correlation analysis since a 
10 8 
7/3 5/3 
26 +. 2 23 i 2 NS 
56 ± 7 65 i . 8 NS 
80 i 5 79 i 8 NS 
17 i 3 10 i 2 ρ < 
0.05 
18 i 4 17 ± 5 NS 
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numerical value of PC 20-histamine was not determined above a histamine concentration 
of 16 mg/ml. Among the patients with histamine hyperresponsiveness several patients 
had severe airflow limitation (e.g. pt. 9: FEV-1 30.7 % pred) whereas others had a 
relatively normal lung function ( e.g. pt.5: FEV-1 95.6 % pred). Baseline lung function 
did not differ between histamine responders and non-responders. The bronchodilator 
response to terbutaline was significantly larger in histamine-responders (17.4 ±_ 2.5 %) 
than in non-responders (9.8 ±_ 2.3 %) (p < 0.05; table 8.2). Seven of 10 histamine-
responders showed significant reversibility of airflow limitation (more than 15 % rise in 
FEV-1) after terbutaline compared to 2 out of 8 non-responders. The response to 
ipratropium bromide was similar in both groups. 
The response to exercise challenge is as follows; The per cent rise in MEF-50 
immediately after exercise was 46.1 ±_ 8.7 % , while FEV-1 increased 12.9 +. 2.1 % 
compared to pre-exercise values. The per cent fall in MEF-50 after exercise was 1.1 ± 
0.8 % and FEV-1 decreased 0.7 ±_ 0.5 % after exercise. Five patients showed relevant 
bronchodilatation (i.e. a more than 15 % rise in baseline FEV-1) immediately after 
exercise. No significant fall in any expiratory airflow parameter was observed after 
exercise. Histamine-responders and non-responders did not differ in their responses to 
exercise (table 8.3). A significant correlation was found between the increase in FEV-1 
immediately post-exercise and the improvement in FEV-1 after inhalation of ipratropium 
bromide (r=0.80; p<0.001)(Fig.8.1). No such correlation existed between the responses 
to exercise and terbutaline (r=0.32;p = 0.2). There was also no relation between baseline 
FEV-1 and the increase in FEV-1 immediately post-exercise (r= -0.29;p=0.24). 
Nine of the 18 adult CF patients (50 %) were atopic as defined by RAST criteria. The 
incidence of reactions to specific allergens was: tree pollen 3 patients, timothy grass 5 
patients, secale cereale 5 patients, Dermatophagoides pteronyssinus 5 patients, aspergillus 
fumigatus 5 patients, house dust 2 patients, dog hair 3 patients, cat fur 3 patients. There 
were no patients with only one positive test result; nine patients had two or more positive 
tests and were considered atopic. Four of these 9 patients regularly used bronchodilators. 
Lung function and bronchodilator responses did not differ between atopic and non-atopic 
patients. The prevalence of atopy was not different between histamine-responders and non-
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responders (Table 8.3). 
AFE^ after 
exercise (%) 
50 
¿0 
30 
20 
10 
— ι 1 1 1 1 1 — 
10 20 30 АО 50 60 
AFEV^ after ipratropium (%) 
Figure 8.1 
Correlation between increase in FEV-1 immediately post-exercise and increase in FEV-1 
after inhalation of ipratropium bromide in 18 adult CF patients. ( Regression analysis r = 
0.80; ρ < 0.001). 
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Discussion 
Bronchial hyperresponsiveness (BHR) to inhaled histamine was observed in 56 % of 
this group of adult CF patients with a wide variety of clinical severity. Others found BHR 
to inhaled histamine in 21 - 40 % of children with CF with mean ages 10-14 years (5-7). 
It is possible that hyperresponsiveness to histamine increases with age in CF patients. A 
conventional histamine challenge test with adherence to a 20 % reduction of baseline 
FEV-1 (% pred) may theoretically not be as relevant in patients with severe airflow 
limitation as in other groups because further narrowing of airways in response to histam-
ine may not occur. Darga et al found that a true hyperreactive response to cold-air 
provocation occurs more in CF patients with mild to moderate disease than in patients 
with severe CF lung disease (22). However, the present study shows that histamine can 
provoke further airflow limitation in CF patients with severe airway obstruction as well. 
Moreover, hyperresponsiveness to histamine, as demonstrated in this study, is not only 
confined to CF patients with airflow limitation (4,5,11). 
The underlying mechanism of BHR in CF is unknown. It has been suggested that 
BHR in CF is genetically determined, associated with abnormalities of the autonomic 
nervous system and with atopy (8,23,24). The CF patients with BHR in the present 
study showed a significantly better bronchodilator response to inhalation of terbutaline 
than patients without histamine hyperresponsiveness, whereas the response to ipratropium 
bromide was not different between both groups. Histamine responsiveness did not 
correlate with atopy. In one study all histamine-responsive CF patients were also atopic on 
skin testing, but a selection bias was introduced since only CF patients with minor 
pulmonary disease were enrolled (5). We and others could not find a correlation between 
atopy and histamine responsiveness (4,6,28). Possibly, BHR in CF is secondary to the 
chronic pulmonary disease since inflammation and epithelial damage alter mucosal 
permeability and histamine penetration (25). Moreover, in the presence of airway 
narrowing and thickening, a small further change in airway calibre produces a larger 
change in airflow resistance on a geometrical basis alone (26,27). It has been shown in 
CF patients that hyperresponsiveness to methacholine is an unfavorable prognostic finding, 
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worsening the prognosis of the pulmonary disease in CF (8). 
The presence of non-specific BHR warrants future prospective investigation with drugs 
that control BHR e.g. inhaled corticosteroids. 
Bronchodilatation was the predominant response to exercise challenge in this group of 
adult CF patients. Using exercise as a test of bronchial responsiveness in CF raises some 
problems. In CF cardiac function does not limit exercise performance, but a reduced 
ventilatory capacity plays the major role in limiting exercise (29). The CF patients tend 
to maintain a high minute ventilation ( VE )during exercise to compensate for an enlarged 
dead space ventilation (30-32). Particularly in more disabled patients, the VE at maximal 
exercise approaches or exceeds the estimated maximum voluntary ventilation, indicating 
that a ventilatory limit has been reached (29). Braggion et al (33) performed several 
different exercise tests in a group of CF patients.with only mild airway obstruction (mean 
FEV-1 77% predicted) and these patients reached a sililar VE (1/kg/min) during exercise, 
when compared to a control group. In our study two patients (no 5 and 11) without 
significant airway obstruction (FEV-1 95 % predicted in both patients) were hyperrespon· 
sive to histamine but showed no exercise-induced bronchoconstriction. However, patients 
with a very low FEV-1 will probably not generate high enough ventilation rates to "dry" 
or "cool" the airways and to get exercise-induced bronchoconstriction. This may be the 
reason why five patients in our study (no: 2,7,9,12,13) with a PC-20 histamine < 2 
mg/ml and a FEV-1 < 50 % predicted did not get exercise-induced bronchoconstriction. 
There are several possible explanations for the bronchodilatation observed during exercise 
in CF patients. Improvement of mucus clearance relieves partially obstructed airways, 
however, this usually does not occur immediately following exercise. Loughlin et al (34) 
showed further that dynamic compression of conducting airways early during a forced 
expiratory maneuvre can produce supramaximal flow transients, thus contributing to peak 
flow. Following exercise, changes in peak flow and correlated changes in the volume of 
the flow transients occurred and an increase as well as a decrease of both flows could be 
observed in their studied group. However, these flow transients would not be expected to 
contribute to MMEF and MEF-25. Since MMEF and MEF-25 also increased during 
exercise, bronchodilatation of peripheral airways may have occurred as well, diminishing 
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the value of this theory of flow transients. The observation that the exercise-induced 
bronchodilatation significantly correlated with the bronchodilatation after ipratropium 
bromide is interesting. It has been found that CF patients show increased activity and 
responsiveness of the cholinergic nervous system (23-24). Moreover there is indirect 
evidence that vagal pathways are involved in exercise-induced asthma (35). An increased 
vagal tone may lead to an increased resting bronchomotor tone which is reduced by 
anticholinergic agents, as demonstrated in this study by the bronchodilator effect of 
ipratropium bromide, and possibly also by exercise. 
Fifty per cent of the studied CF patients were atopic as defined by RAST criteria. 
Lung function and response to histamine and bronchodilators did not differ between atopic 
and nonatopic subjects. An impaired clearance of trapped antigens in the viscid bronchial 
mucus and the abnormal permeability of the damaged bronchial mucosa might cause an 
increased antigen exposure to IgE producing submucosal cells which may explain this high 
incidence of atopy (28). This is in accordance with the observation that the frequency of 
positive skin tests in CF increases with age (4). By contrast with the hyperresponsive-
ness to methacholine, which has clear prognostic implications, the presence of atopy has 
not shown to be related to severity and prognosis of CF. The results of this study also 
confirmed that. Atopy does not predict the patients' response to bronchodilators, to 
histamine or to exercise. 
In conclusion, this study demonstrates that bronchial responsiveness to histamine is 
prevalent in a high proportion of adult CF patients with a wide variety of clinical severity 
and is not confined to patients with severe airflow limitation. Bronchial responsiveness to 
histamine is related to bronchodilator responsiveness to the Bcta-2-agonist tcrbutaline, but 
not to atopy. The presence of atopy in CF patients is of minor importance and does not 
give information on bronchial responsiveness to bronchodilators, exercise or histamine. 
Exercise improves expiratory airflow without necessarily causing bronchoconstriction and 
the bronchodilator response after ipratropium bromide correlates well with the exercise-
induced bronchodilatation. An increased vagal tone in CF patients may lead to an 
increased resting bronchomotor tone which can be reduced by ipratropium bromide and 
exercise. 
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Summary 
Bronchial hyperresponsiveness is present in 40 -60 % of adult patients with cystic fibrosis 
(CF). Drugs which alter airway hyperresponsiveness have not been studied in CF so far. 
In this randomized placebo-controlled study we investigated the effects of an inhaled 
corticosteroid, budesonide, on lung function and bronchial hyperresponsiveness in adult 
CF patients with proven bronchial hyperresponsiveness to histamine. Twelve patients 
were treated with budesonide, 1600 meg daily, and with placebo during two periods of six 
weeks in a randomized double-blind cross-over study. Drug effects were assessed with 
regard to bronchial hyperresponsiveness to histamine, spirometry and clinical symptoms 
scores. After treatment with budesonide, no significant differences in spirometry were 
seen, however, bronchial hyperresponsiveness to histamine significantly improved as 
compared to baseline. 58 % of the patients showed a more than one doubling-dose 
increase in PC-20 histamine. Daily symptom scores showed small but statistically signifi-
cant improvements in dyspnoea and cough after budesonide treatment. No increased 
frequency of infective exacerbations was seen during budesonide treatment. There is 
increasing evidence suggesting that excessive inflammatory responses contribute to the 
pulmonary damage that characterizes CF. Treatment with oral corticosteroids improved 
the clinical course of selected CF patients but was associated with unacceptable adverse 
effects. We conclude that daily inhalation of 1600 meg budesonide for six weeks induced 
a small but significant improvement in bronchial hyperresponsiveness to histamine and 
symptoms of cough and dyspnoea in adult CF patients. Longer observations are needed 
to establish whether inhaled corticosteroids improve the long term outcome of CF. 
Introduction 
Bronchial hyperresponsiveness is a functional characteristic of bronchial asthma. Its 
presence can be demonstrated by assessing the bronchoconstrictor response to inhaled 
pharmacologic agents like histamine and methacholine. Patients with cystic fibrosis (CF) 
show this hyperresponsiveness to inhaled stimulants in 40-60 % (1-4). The mechanism of 
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bronchial hyperresponsiveness in CF is unclear, although a relation with the underlying 
airway disease has been suggested (2). Existing airway narrowing and thickening of the 
airway wall may alter the airway geometry to such an extent that a small increase in 
degree of narrowing produces a greater relative change in cross-sectional area (5). In 
addition, chronic inflammation may enhance the mucosal permeability and allow better 
penetration of histamine to bronchial smooth muscles and 'irritant' receptors (6). 
However, observations that the FEV-1 is lower in hyperresponsive CF patients (2,4,7) 
than in non-hyperresponsive CF patients, are not confirmed by other authors (3,8). 
Others have suggested that airway hyperresponsiveness in CF is a genetically determined, 
systemic abnormality, associated with abnormal autonomic responses (9,10). Regardless 
its cause, bronchial hyperresponsiveness in CF appears to be an unfavorable prognostic 
finding as demonstrated in a prospective study in which the natural history of lung disease 
was more severe in hyperresponsive CF patients (2). In patients with allergic asthma, 
treatment with inhaled corticosteroids induces a clear change in bronchial hyperres-
ponsiveness, expressed by increases in tolerance to histamine and ultrasonically nebulized 
distilled water, improvement of lung function and clinical symptom scores (11-13). Drugs 
which alter airway hyperresponsiveness have not been studied in CF so far. 
In this randomized placebo-controlled study we therefore investigated the effects of an 
inhaled corticosteroid , budesonide, on lung function and bronchial hyperresponsiveness in 
adult CF patients with proven bronchial hyperresponsiveness to histamine. 
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Subjects and Methods 
Subjects. 
Sixteen CF patients (mean age 27; range 16-45) volunteered to participate in the study. 
The diagnosis CF was established by sweat test. All patients 
has a baseline FEV-1 above 25 per cent of predicted values (14), absence of a recent ( < 
6 weeks ) acute pulmonary exacerbation and a PCj,, FEV-1-histamine below 16 mg/ml. 
Excluded were patients with pregnancy, use of oral corticosteroids or the presence of 
severe concomitant disease which might interfere with the study and performing the tests. 
The study was approved by the hospital's Medical Ethics Committee and written informed 
consent was obtained from all subjects. 
Methods. 
The study consisted of 3 periods. Period one was a run-in period of 2 weeks and periods 
2 and 3 were double blind, placebo-controlled, cross-over medication periods of 6 weeks. 
At the first and last day of the run-in period and at the last day of each treatment period 
the patients underwent spirometry and a histamine provocation test. Inhaled bronchodila-
tors were withheld for at least 12 hours prior to each visit while test medication was 
continued normally. Throughout the entire study, patients maintained a diary of symp-
toms and daily Peak Expiratory Flow Rate (PEFR) measurements. The best of three 
PEFR measurements was scored twice daily before medication use. On each day scores 
for dyspnoea at rest and during exercise, cough and sputum production were recorded (0-
3: 0 = no complaints, 3 = severe complaints). Only 3-2-agonists were allowed to be 
used as bronchodilators if necessary and their use was recorded. Prophylactic antibiotics, 
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pancreatic enzymes and vitamins supplementation when appropriate, were continued 
throughout the trial. Sodium cromoglycate, antihistamines and theophylline preparations 
were stopped prior to the study protocol. Lung function tests were performed with a 
standard wet spirometer ( Pulmonet III, SensorMedics, Bilthoven, The Netherlands). 
Allergy status was checked by RAST tests for 10 common inhalational allergens. Allergy 
was defined as at least one positive test result by the RAST method. Standardized 
histamine provocation tests were performed and computerized calculations of the provoca-
tive concentration of histamine producing a 20 % fall in FEV-1 ( PC ,^ histamine ) were 
made (IS). A pulmonary exacerbation of CF was reason for removal from the trial. 
Blinded metered dose inhalers were supplied by ASTRA Pharmaceutica, Rijswijk, The 
Netherlands. The inhalers contained budesonide with 200 meg per puff, or placebo. Four 
puffs were inhaled two times a day via a spacer device (Ncbuhaler). 
Statistics 
Diary card parameters and PEFR values were averaged over the two week run-in period 
and over the last two weeks in the two treatment periods. The Wilcoxon test for paired 
differences was used on lung function data, log PCM, mean PEFR and symptom scores. 
Five percent was taken as the level of significance. Data are expressed as means N SEM. 
Results 
Of the 16 patients who started the study, 12 patients provided complete data for analysis. 
Patient characteristics are given in Table 1. 
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Patient M / F Age FEV-1 allergy 
% Pred 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
M 
M 
M 
M 
M 
M 
F 
F 
M 
M 
F 
F 
28 
23 
29 
27 
31 
26 
25 
29 
22 
16 
24 
34 
51 
24 
98 
32 
85 
55 
37 
75 
87 
78 
41 
50 
+ 
+ 
+ 
-
-
-
-
-
+ 
-
-
_ 
mean 26 59 
sem 2 7 
Table 9.1: Patient characteristics. 
Two patients were withdrawn from the study because of noncompliance, both during 
placebo treatment. One patient was withdrawn from the trial after a viral illness and 
subsequent exacerbation of airways infection with Pseudomonas aeruginosa during 
treatment with budesonide, whereas the fourth patient was withdrawn after a trauma 
(broken leg). The airways were colonized with Pseudomonas aeruginosa in 8 patients (no 
1,2,4,6,7,9,11,12), with haemophilus influenza and staphylococcus aureus in 1 patient (no 
5), with staphylococcus aureus alone in one patient (no 8) whereas the remaining two 
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patients (no 3,10) did not have bacterial colonization of their airways at the time of the 
study. 
The results of baseline spirometry before and after the two weeks run-in period were 
comparable within a 5 % range. Also the PCW histamine levels showed a good reprodu­
cibility: the Log PCjo values were 0.22 ±_ 0.15 before, and 0.22 ±_ 0.18 at the end of the 
run-in period. During placebo treatment, no significant changes occurred in any of the 
spirometrie values (Table 2). Also, the mean Log PC20 histamine after placebo was not 
significantly different from baseline. 
After 6 weeks treatment with budesonide small, but not significant changes were observed 
in FEV-1 and F VC (Table 2). None of the patients showed an increase in baseline FEV-1 
(1) of > 15 % after budesonide. The mean Log PCM histamine increased after budesoni­
de from 0.22 to 0.50 (p < 0.01). The geometric mean РСвд histamine increased from 
1.6 to 3.2 mg/ml, the difference being small but statistically significant. Seven patients 
showed a more than one doubling dose increase in PC20 histamine (Figure 1). Of these 7 
patients, 2 were allergic. No correlation was found between the improvement in РС
М
 and 
the change in FEV-1. Daily symptom scores, peak expiratory flow rate measurements 
and the use of 3- agonists were collected from the diary cards. The mean diurnal variation 
of PEFR was 3.9 % and did not change during treatment periods. None of the individual 
patients showed a diurnal variation of PEFR > 10 %. A small improvement in 
the scores for dyspnoea at rest (p = 0.02) and cough (p = 0.03) could be observed after 
budesonide treatment in comparison with placebo (Table 2). The other parameters showed 
no significant differences between the two treatment periods. No increased frequency of 
infective exacerbations was seen after budesonide treatment. No side effects were reported 
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by the patients. The results of all tests were not significantly different between allergic 
and non-allergic subjects. 
Spirometry values 
FEV-1 (L) 
FVC (L) 
MEF-50 (L/min) 
Diary card scores (0-3) 
dyspnoea at rest 
dyspnoea on exercise 
cough 
sputum production 
morning PEFR (l/min) 
evening PEFR (l/min) 
3-agonist use 
baseline 
2.3 
3.5 
1.7 
0.47 
0.73 
1.19 
2.2 
433 
449 
1.2 
placebo 
2.2 
3.3 
1.7 
0.54 
0.97 
1.20 
2.3 
416 
442 
1.2 
budesonide 
2.3 
3.6 
1.9 
0.38 
0.98 
1.14 
2.3 
421 
443 
1.1 
p-value 
NS 
NS 
NS 
ρ < 0.05 
NS 
ρ < 0.05 
NS 
NS 
NS 
NS 
Table 9.2: Effects of treatment with placebo and budesonide on lung 
function, symptom scores, daily peak flow expiratory rate and 
3-agonist use (puffs/day) in 12 adult patients with cystic 
fibrosis (mean values). P-values denote significant differences 
between values after placebo and values after budesonide. 
Baseline data represent values after the run-in period. 
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PC-20 histamine 
mg/ml 
0.5 
BASELINE BUDESONIDS 
Figure 9.1 
Individual data (.) and mean values (-) of PC-20 histamine 
levels (mg/ml) before and after 6 weeks of treatment with 1600 
meg budesonide in 12 adult CF patients. 
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Discussion 
The results of this study indicate that treatment with inhaled corticosteroids decreases 
bronchial hyperrcsponsiveness in adult patients with CF. This is the first study showing 
that the severity of bronchia] hyperresponsiveness in CF patients can be decreased with 
anti-inflammatory therapy. In patients with asthma long term treatment with inhaled 
corticosteroids showed clear improvement in bronchial hyperresponsiveness, lung function 
and clinical symptom scores (11,12,19,20). The efficacy of inhaled corticosteroids is 
controversial in COPD. Several studies have shown no significant improvement in FEV-1 
or bronchial responsiveness to histamine in an overall population of COPD patients treated 
with inhaled corticosteroids (16-18). In non-CF patients with bronchiectasis, lung 
function, cough and sputum production improved significantly after the daily inhalation of 
1500 meg beclomethason during 6 weeks (21). Treatment with inhaled sodium cromogly-
cate in CF patients showed no beneficial effects on symptoms, pulmonary function tests or 
methacholine responsiveness (22). Controlled trials using inhaled corticosteroids in CF 
patients have not been reported yet. A retrospective study showed some beneficial effects 
on lung function of treatment with inhaled steroids as adjunct to antibiotics in selected CF 
patients during an exacerbation of airways infection (23). We performed a double-blind, 
placebo-controlled cross-over trial with high dose budesonide and found a beneficial effect 
on bronchial hyperresponsiveness. 
The decrease in PC20 histamine was not accompanied by an increase in spirometeric 
values. It is possible that the number of patients limited the statistical power of the trial 
to detect small changes. Daily symptom scores showed small, but significant, improve-
ments in dyspnoea at rest and in cough. Seven of the 12 patients showed a more than one 
doubling dose increase in PCj,, histamine. The improvement in PC20 could not be 
attributed to improvement in bronchial caliber because no correlation existed between the 
change in PC ,^ and the change in FEV-1, if present. Although the observed beneficial 
effects of an inhaled corticosteroid on this group of adult CF patients were small, the 
results are encouraging. Whether a longer observation period than 6 weeks, and doses of 
budesonide above 1600 meg would provide stronger beneficial effects on lung function 
remains to be determined. 
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The attenuation of bronchial hyperresponsiveness without concomitant change in 
airway calibre might reflect a decrease in epithelial permeability and/or the presence of 
inflammatory cells and mediators. Eggleston et al have shown that in patients with CF 
bronchial hyperresponsiveness is an unfavorable prognostic finding, associated with more 
rapid pulmonary deterioration (2). In the CF lung, elevated levels of neutrophil proteases, 
such as elastase, tumour necrosis factor and interleukin-8 suggest a self-perpetuating 
inflammatory process on the bronchial surface (24,25). Several data suggest the existence 
of an excessive inflammatory immune-response in the lungs of CF patients (26). In this 
view the use of the non-steroidal-anti-inflammatory-drug Ibuprofen was investigated in a 
rat model of chronic Pseudomonas endobronchial infection. Ibuprofen significantly 
decreased the extent of the inflammatory response without increasing the pulmonary 
burden of bacteria (27). Following also the concept of hyperinflammation, several trials 
of immunosuppressive therapy using oral corticosteroids have been performed in CF 
patients. A short-term trial of 0.5 mg/kg Prednisolon daily during 3 weeks in 15 CF 
patients with severe airflow obstruction showed no significant improvement in spirometry 
or clinical condition (28). However, in a long-term controlled study with 2 mg/kg 
Prednisolon on alternate days, significant beneficial effects (better lung function, less 
hospital admissions) were seen in a group of 45 children with CF, aged 1-12 years (29). 
These results suggest that the corticosteroid therapy had modulated the excessive immune 
response. Unfortunately, longer follow up of CF patients treated with oral corticosteroids 
showed a variety of important and unacceptable adverse effects, such as substantial growth 
retardation, early cataract formation and glucose intolerance (30,31). Therefore, at 
present, chronic oral corticosteroid treatment cannot be recommended. 
In summary, there is increasing evidence to suggest that excessive inflammatory 
responses contribute, at least in part, to the pulmonary damage that characterizes CF. In 
this study of adult CF patients we found that daily inhalation of 1600 meg budesonide for 
6 weeks induced a small but significant improvement in bronchial responsiveness to 
histamine and symptoms of cough and dyspnoea. This was not accompanied by an 
increased frequency of infective exacerbations. Longer observations are needed to esta-
blish whether inhaled corticosteroids improve the long term outcome of CF. 
124 
1. Van Haren EHJ, Lammers J-WJ, Festen J, Van Herwaarden CLA. Bronchodilator 
response in adult patients with cystic fibrosis: effects on large and small airways. 
Eur Respir J, 1991,4,301-307. 
2. Egglcston PA, Roscnstein BJ, Stackhouse CM, Alexander MF. Airway hyperreac-
tivity in cystic fibrosis: clinical correlates and possible effects on the course of the 
disease. Chest, 1988, 94,360-365. 
3. van Asperen P, Mellis CM, South RT, Simpson SJ. Bronchial reactivity in cystic 
fibrosis with normal pulmonary function. Am J Dis Child, 1981, 135, 815-819. 
4. Mitchell I, Corey M, Woenne R, Krastins IRB, Levison H. Bronchial hyperreacti-
vity in cystic fibrosis and asthma. J Pediatrics, 1978, 93, 744-748. 
5. Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Bronchial responsiveness 
to methacholine in chronic bronchitis: relationship to airflow obstruction and cold 
air responsiveness. Thorax, 1984,39,912-918. 
6. Boushey HA, Holtzman MJ, Sheller JR, Nadel TA. Bronchial hyperreactivity: 
State of the art. Am Rev Respir Dis, 1980,121, 389-413. 
7. Mellis CM, Levison H. Bronchial reactivity in cystic fibrosis. Pediatrics, 1978, 
61, 446-450. 
8. Tobin MJ, Maguire O, Reen D, Tempany E, Fitzgerald MX. Atopy and bronchial 
reactivity in older patients with cystic fibrosis. Thorax, 1980, 35, 807-813. 
9. Davis PB. Autonomic and airway reactivity in obligate heterozygotes for cystic 
fibrosis. Am Rev Respir Dis, 1984, 129, 911-914. 
10. Davis PB, Shelhamer JR, Kaliner M. Abnormal adrenergic and cholinergic 
sensitivity in cystic fibrosis. New Engl J Med, 1980, 302, 1453-1456. 
11. Molema J, van Herwaarden CLA, Folgering HTM. Effects of long term treatment 
with inhaled budesonide and cromoglycate on bronchial hyperresponsiveness in 
patients with allergic asthma. Eur Respir J, 1989, 2, 308-316. 
12. Juniper LF, Kline PA, Vanzieleghem MA, Ramsdale H, O'Byrne PM, Hargreave 
125 
FE. Effect of long term treatment with an inhaled corticosteroid (budesonide) on 
airway hyperresponsiveness and clinical asthma in nonsleroid-dependent 
asthmatics. Am Rev Respir Dis, 1990, 142, 832-836. 
13. Groot CAR, Lammers J-WJ, Molema J, Festen J, van Herwaarden CLA. Effects 
of inhaled beclomethasonc and nedocromil sodium on bronchial hyperresponsive-
ness to histamine and distilled water. Eur Respir J, 1992,1075-1082. 
14. Quanjer Ph. Standardized lung function testing. Bull Eur Path Resp, 1983, 19 
(suppl.5),7-95. 
15. Cockcroft DW, Kilian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to 
inhaled histamine: a method and a clinical survey. Clin Allergy, 1977, 7,235-243. 
16. Chung KF. Long term inhaled corticosteroid therapy in chronic airways obstructi-
on. Eur Respir J, 1992,5,913-914. 
17. Watson A,Lim TK.Joyce H,Pride NB. Trial of the effect of inhaled corticosteroids 
on bronchoconstrictor and bronchodilator responsiveness in middle aged smokers. 
Thorax,1988,43,231. 
18. Auffarth B, Postma DS, De Monchy JGR, van de Mark TW, Boorsma M.Koeter 
GH. Effects of inhaled budesonide on spirometrie values, reversibility, airway 
responsiveness and cough threshold in smokers with chronic obstructive lung 
disease. Thorax,1991,46,372-377. 
19. Dompeling E, Van Schayk CP, Van Grunsven et al. Slowing the deterioration of 
asthma and chronic obstructive pulmonary disease observed during bronchodilator 
therapy by adding inhaled corticosteroids. Ann Int Medicine, 1993, 118, 770-778. 
20. Kcrstjens HAM, Brand PLP,Hughes MD et al. Comparison of bronchodilator 
therapy with and without inhaled corticosteroid therapy for obstructive airways 
disease. New Engl J Med, 1992,327,1413-1419. 
21. Elbom JS, Johnston B.Clarke J.McGarry J.Varghese G. Inhaled steroids in 
patients with bronchiectasis. Respiratory Medicine, 1992,86,121-124. 
22. Sivan Y.Arce P,Eigen H.Nickerson BG.Newth CJL. A double-blind,randomized 
study of sodium cromoglycate versus placebo in patients with cystic fibrosis and 
bronchial hyperreactivity. J Allergy Clin Immunol, 1990, 85,649-654. 
126 
23 Nikolaizik WH, Schoni MH. Effect of inhaled corticosteroids on lung function in 
cystic fibrosis patients. Eur Respir J, 1993, 6, suppl 17, 231S (abstract). 
24 Norman D, Elborn JS, Cordon SM, Rayner RJ, Wiseman MS, Hiller EJ, Shale 
DJ. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax, 1991, 46, 91-
95. 
25 Nakamura H, Yoshimura K, McEIvaney NG, Crystal RG. Neutrophil elastase in 
respiratory epithelial lining fluid of individuals with cystic fibrosis induces 
interleukin-8 expression in a human bronchial epithelial cell line. J Clin In-
vest, 1992,89,1478-1484. 
26. Berger M. Inflammation in the lung in cystic fibrosis. Clin Reviews in Aller-
gy,1991,9, 119-142. 
27. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory 
response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infecti-
on. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir 
Dis, 1990, 141, 186-192. 
28. Pantin CFA, Stead RJ, Hodson ME, Batten JC. Prednisolone in the treatment of 
airflow obstruction in adults with cystic fibrosis. Thorax, 1986, 41,34-38. 
29. Auerbach HS, Williams M.Kirkpatrick JA, Colten HR. Alternate day prednisone 
reduces morbidity and improves pulmonary function in cystic fibrosis. Lan-
cet,1985,ii,686-688. 
30. Donati MA, Haver K, Gerson W et al. Long term alternate day prednisone therapy 
in cystic fibrosis. Pediatr Pulmonol, 1990,suppl 5, 277. 
31. Rosenstein BJ, Eigen H. Risks of alternate day prednisone in patients with cystic 
fibrosis. Pediatrics, 1991, 87,245-246. 
127 

Chapter 10 
Summary, conclusions and considerations. 

Cystic fibrosis (CF) is the most prevalent fatal inherited disease in Caucasians. Improve-
ment in therapy has lengthened life expectancy of children and many patients now survive 
into adolescence. Pulmonologists and gastroenterologists therefore will increasingly be 
involved in the care of adult CF patients. Respiratory and intestinal complications account 
for most of the morbidity and more than 90 per cent of all CF patients die of respiratory 
insufficiency. It is important that the functional disturbances of the pulmonary and 
digestive systems are detected, and treated when necessary, at an early stage. Reported 
studies in the literature on the function of the pulmonary and digestive systems mainly 
concern children. The general aim of this thesis is the investigation of functional aspects 
of the respiratory and digestive tract in adult CF patients. 
In Chapter 3 we describe the results of a retrospective analysis of digestive disorders in 
adult CF patients. Symptoms of liver, pancreatic and intestinal disorders occurred before 
and/or after the presence of respiratory symptoms. Exocrine pancreatic insufficiency was 
present in 80 % of the investigated adult CF patients. Several patients with normal faecal 
fat excretion suffered from recurrent pancreatitis and we suggest to consider the diagnosis 
of CF in young patients with unexplained recurrent pancreatitis. Deficiency of the fat-
soluble vitamins D and E was present in most patients with steatorrhea. In 20% of the 
adult CF patients we observed the distal intestinal obstruction syndrome (DIOS). Proper 
diagnosis and treatment is important for this potentially dangerous intestinal disorder. 
Disturbed biochemical liver function tests were observed in many patients. Overt liver 
cirrhosis is only present in 2-5 % of adult CF patients. As demonstrated, liver disorders 
may be the presenting sign of CF. Diagnosis and treatment of liver disorders in CF are 
discussed in chapter 3. 
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In Chapter 4 the literature on pulmonary disease in CF is reviewed. A wide range of 
severity of pulmonary disease can be observed and considerable differences exist between 
patients in the rate at which respiratory function declines. Abnormalities in pulmonary 
function tests parallel and reflect the pathophysiological processes. The effects of 
bronchodilators and the presence of bronchial hyperresponsivencss are described in 
chapters 7 and 8. Bacterial infection and colonization cause infective exacerbations and 
worsening of pulmonary function. The relevance of viral and mycobacterial infections, in 
this respect, is still controversial. Important respiratory complications in CF include 
haemoptysis, pneumothorax and allergic bronchopulmonary aspergillosis. The manage-
ment of these complications is discussed in chapter 4. The progress in our knowledge of 
the genetic abnormality in CF offers opportunities for more causal and genetic therapeutic 
approaches in the future. Lung transplantation is a viable option for the treatment of CF 
patients with end-stage lung disease and a short life-expectancy. It is, however, not a cure 
and careful monitoring of pulmonary and intestinal disorders remains essential for all pa-
tients. 
In Chapter 5 the exocrine and endocrine functions of the pancreas and the morphologic 
characteristics of the pancreas were studied in adult CF patients and compared with a 
control group of normal subjects. Ultrasonographic examination of the pancreas showed a 
larger pancreatic head and a smaller pancreatic body in the CF patients. It seems that the 
pathological process in CF has a more severe damaging effect on the pancreatic body, 
initially sparing the pancreatic head. The described selective uptake of selenomethionine in 
only the pancreatic head of CF patients, supports this hypothesis. The basal and post-
prandial plasma pancreatic polypeptide (PP) levels were strongly reduced in all CF 
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patients. In patients with chronic pancreatitis, the PP secretion often remains normal until 
the pancreas is severely damaged and clinically overt steatorrhea has occurred. In the CF 
patients basal and postprandial plasma PP levels correlated well with pancreatic body 
diameter, suggesting that pancreatic atrophy, fibrosis and fatty infiltration is accompanied 
by an early decrease in number and/or function of the PP cells. The insulin secretion in 
response to meal ingestion was blunted but still significant in the CF patients. The insulin-
producing cells are obviously less susceptible to the damaging process of the pancreas in 
CF than the PP cells and the exocrine pancreatic tissue. Urinary excretion of n-para-ami-
nobenzoic acid (n-PABA) was reduced in the CF patients with and without steatorrhea. 
The secretin-cholecystokinin stimulation test showed that CF patients, regardless of their 
ability to produce adequate pancreatic enzyme output, have an abnormality of pancreatic 
fluid and bicarbonate secretion. To determine this discrepancy between acinar and ductu-
lar exocrine pancreatic function, both secretin and cholecystokinin stimulation testing is 
necessary. The demonstration of characteristic features with ultrasonography and with 
exocrine and endocrine pancreatic function tests can support the diagnosis of CF in case 
of borderline or non-informative sweat test results. For general clinical practice it can be 
recommended that in the management of adult CF patients regular determination of 
steatorrhea, serum levels of fat soluble vitamins and glucose is sufficient for monitoring 
pancreatic function. 
Cholelithiasis is another frequent complication of CF, present in 6-30 % of adult pa-
tients. A diminished plasma cholecystokinin (CCK) secretion and gallbladder contraction 
could both affect fat maldigestion and contribute to the formation of gallstones. Low 
plasma CCK levels and a reduction in gallbladder emptying have been found recently in 
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patients with severe pancreatic insufficiency due to chronic pancreatitis. Therefore, we 
have measured plasma CCK levels and gallbladder volumes before and after ingestion of a 
standard breakfast in adult CF patients and in normal control subjects. The results of these 
measurements are presented in Chapter 6. In the CF patients basal and maximal postpran-
dial plasma CCK levels were significantly higher than in the control subjects. The integra-
ted plasma CCK secretion in response to the test meal was similar in CF patients and 
controls. The elevated CCK levels in CF most probably do not result from diminished 
intraluminal pancreatic enzyme activity, but are related to a reduced feedback inhibition of 
CCK-producing cells by intraluminal bile salts. Plasma CCK levels in man are inversely 
related to the presence of luminal bile salts. It is therefore suggested that a small bile-acid 
pool size and a reduction of bile-acid output into the duodenum contributes, at least in 
part, to the observed increased plasma CCK levels before and after ingestion of a meal in 
adult CF patients. The elevated plasma CCK levels in CF might be involved in the 
pathogenesis of gastro-oesophageal reflux since CCK is known to reduce lower oesopha-
geal sphincter pressure. In CF patients an increased frequency of gastro-oesophageal 
reflux is observed. The increased plasma CCK levels in the CF patients were accompa-
nied by reduced gallbladder volumes in both the basal and the postprandial state. Small 
gallbladder volumes may compromise storage of bile acids in the gallbladder and thereby 
contribute to the smaller bile-acid pool and reduced total bile-acid output into the 
duodenum as observed in CF. Postprandial gallbladder emptying, expressed as a percenta-
ge of basal volume, was well preserved in the CF patients. Therefore, neither impaired 
CCK release nor impaired gallbladder emptying contribute to the development of fat 
maldigestion and gallstones in adult CF patients. 
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In the studies described in chapter 7 we performed maximal expiratory flow volume 
curves ( MEFV-curves ) and baseline spirometry including total lung capacity measure-
ment with a helium dilution method in 20 adult CF patients. A bodyplethysmograph was 
used to measure airway resistance and total lung capacity. Most patients showed 
prominent bronchial obstruction and seven patients also showed signs of restrictive 
pulmonary disease. Large differences were observed between total lung capacity as 
measured by means of bodyplethysmography and the helium dilution technique. For 
calculations we defined a modified "air-trapping index". This index correlated significant-
ly with MEF-50 and MEF-25 values and the RV/TLC ratio and it represented important 
airtrapping due to peripheral airway obstruction, present in most patients. We also 
investigated the bronchodilator effects of different doses of terbutaline and ipratropium 
bromide with regard to magnitude and preferential site of action in the adult CF patients. 
Series of MEFV-curves with air and with He-02 ( heliox, i.e. 80 % helium and 20 % 
oxygen) were obtained before and after inhalation of different doses of terbutaline and 
ipratropium bromide. From the MEFV-curves we calculated the density dependence of 
expiratory flow expressed as delta-MEF-50. Inhalation of terbutaline and ipratropium 
bromide induced significant dose-related bronchodilation. A clinically relevant bronchodi-
lator response, defined as a more than 15 % increase in FEV-1, was found in 70 % of the 
patients. The magnitude of bronchodilation induced by terbutaline did not differ from that 
induced by ipratropium bromide. Most of the adult CF patients were "nonresponders" for 
HE-02 ( delta MEF-50 < 20 %), which is compatible with predominant peripheral 
airway obstruction. Terbutaline induced a significant and consistent increase in delta 
MEF-50 , whereas ipratropium bromide had no effect on density dependence of expiratory 
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flow. Therefore, it seems that terbutaline mainly caused dilation of the peripheral 
airways, whereas ipratropium bromide presumably dilates large and small airways 
equally, leaving density dependence relatively unchanged. In contrast to previous studies 
in children with CF, we did not observe any negative responses to bronchodilators in our 
adult CF patients. For clinical practice we recommend to determine bronchial responsive­
ness to both beta-adrenergic and anlimuscarinic bronchodilators in all individual CF pa­
tients. 
In the study presented in chapter 8 we investigated the presence of bronchial responsi­
veness to histamine, exercise and bronchodilators and the presence of atopy in 18 adult 
CF patients. Histamine responsiveness ( PC20 histamine < 8 mg/ml) was observed in 10 
patients (56%) and was not confined to those with severe airway obstruction. The 
bronchodilator response to terbutaline was significantly larger in the patients with 
histamine responsiveness as compared to the patients without histamine responsiveness. 
Exercise challenge induced a bronchodilator response as indicated by an increase in FEV-
1 and MEF-50. No exercise-induced bronchoconstriction was observed. Histamine 
responsiveness was not correlated to exercise responsiveness. The increase in FEV-1 
measured immediately after exercise was significantly correlated (r = 0.80; ρ < 0.001) 
to the improvement in FEV-1 after inhalation of ipratropium bromide. It has been 
reported in the literature that CF patients show increased activity and responsiveness of 
the cholinergic nervous system. Moreover, there is indirect evidence that vagal pathways 
are involved in exercise-induced asthma. An increased vagal tone may lead to an 
increased resting bronchomolor tone which can be reduced by ipratropium bromide and by 
exercise in adult CF patients. Using a standard radio allergosorbent test (RAST) for 10 
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common inhalational allergens we found positive test results in 9 of the 18 patients 
studied. These patients had two or more positive tests and were considered atopic. Atopic 
and nonatopic subjects did not differ in lung function and response to histamine and 
bronchodilators. Both an impaired clearance of inhaled allergens and the abnormal 
permeability of the damaged bronchial mucosa induce an increased antigen exposure 
locally in the airways, which may explain this high incidence of atopy. This is in 
agreement with observations that in CF patients the frequency of positive skin tests 
increases with age. The presence of atopy has not been shown to be related to severity 
and prognosis of CF. Although of pathophysiological interest, the presence of atopy in CF 
has no clinical importance. The underlying mechanism of bronchial responsiveness to his-
tamine in CF is unknown. It has been shown that hyperresponsiveness to methacholine is 
an unfavourable prognostic finding in CF patients. It is possible that in CF patients 
responsiveness to histamine increases with age. The high prevalence of nonspecific 
bronchial hyperresponsiveness warranted further investigation with inhaled corticosteroids 
, which was the subject of the study presented in chapter 9. 
In the study presented in chapter 9 we describe the results of a double-blind, placebo-
controlled cross-over study of the effects of an inhaled corticosteroid, budcsonide, on 
lung function and bronchial responsiveness in adult CF patients with proven bronchial 
hyperresponsiveness to histamine. Sixteen patients were treated with budesonide, 1600 
meg daily, and with placebo during two periods of six weeks in a randomized double-
blind cross-over study. Drug effects were assessed with regard to bronchial hyperres-
ponsiveness to histamine, spirometry and clinical symptoms scores. After treatment with 
budesonide, no significant differences in spirometry were observed. Bronchial hyperres-
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ponsiveness to histamine, however, significantly improved as compared to baseline, the 
geometric mean PC20 histamine increased from 1.6 to 3.2 mg/ml (p < 0.01). Fifty-eight 
per cent of the patients showed an increase in PC^ histamine of more than one doubling-
dose. Daily symptom scores showed small but significant improvements in dyspnoea and 
cough after budesonide treatment. 
There is increasing evidence suggesting that excessive immune responses contribute to the 
pulmonary damage that characterizes CF. In this respect CF is different from asthma and 
COPD . Treatment with oral corticosteroids improved the clinical course of selected CF 
patients but was associated with unacceptable adverse effects. Our study is the first to 
report the effects of inhaled corticosteroids in CF patients, prospectively. We concluded 
that daily inhalation of 1600 meg budesonide for six weeks induces a small but significant 
improvement in bronchial hyperresponsiveness to histamine and alleviates symptoms of 
cough and dyspnoea in adult CF patients. This was not accompanied by an increased 
frequency of infective exacerbations. Longer observations are needed to establish whether 
inhaled corticosteroids improve the long-term outcome of CF. 
In summary, this thesis decribes functional investigations of pulmonary and digestive 
disorders in adult CF patients. Many of the described investigations can be performed in 
individual patients in routine clinical practice and are helpful for optimal therapy of the 
pulmonary and intestinal disorders present in adult CF patients. Also, these studies open 
perspectives for further research in the future: 
- Investigation of morphologic characteristics from autopsy studies and high-resolution CT 
scanning in correlation with functional disturbances of lung physiology. 
- Determination of the influence and interaction of bronchodilators and inhaled corti-
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costeroids on the long-term outcome of CF. 
The increased survival of CF patients and the recognition of milder forms of CF diagno-
sed in older patients implicate that more pulmonologists and gastroenterologists will be 
involved in the management and care of this complicated disease. CF patients should be 
treated in specialized centres where greater experience with this disease ensures better 
care than that provided by a district hospital. In these centres medical experience and 
research can evolve. Although developments in gene therapy and lungtransplantation 
technology look promising for the welfare of CF patients, investigation and treatment of 
pulmonary and digestive disorders are at least as important challenges for modem medici-
ne. 
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Çeperal conclusions 
1) Adult CF patients show characteristic abnormalities at exocrine and endocrine pancrea-
tic function testing. 
2) Basal and maximal postprandial plasma cholecystokinin levels are significantly elevated 
in adult CF patients. 
3) The increased plasma cholecystokinin levels in adult CF patients are accompanied by 
reduced gallbladder volumes in both the basal and postprandial state. Postprandial 
gallbladder emptying is well preserved. 
4) The diagnosis of CF should be considered in young patients with unexplained recurrent 
pancreatitis or liver cirrhosis. 
5) Due to considerable air-trapping, measurement of static lung volumes in CF patients 
should be performed with a bodyplethysmograph. 
6) Bronchial responsiveness to histamine is prevalent in a high proportion of adult CF 
patients with a wide variety of clinical severity and is not confined to patients with severe 
airflow limitation. 
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7) Inhalation of both 32-agonists and muscarinic receptor antagonists causes dose-related 
bronchodilatation in adult CF patients, where the 32-agonists appear to have more effect 
on peripheral airways, whereas ipratropium bromide induced a more generalized broncho-
dilatation. 
8) Bronchial responsiveness to histamine in adult CF patients is related to bronchodilator 
responsiveness to the beta-adrenoreceptor agonist terbutaline. 
9) The presence of atopy in adult CF patients does not provide information on bronchial 
responsiveness to bronchodilators, exercise or histamine and seems of minor clinical 
importance. 
10) In adult CF patients exercise improves expiratory airflow without causing bronchocon-
striction and this bronchodilator response correlates well with the bronchodilatation 
induced by the muscarinic receptor antagonist ipratropium bromide. An increased vagal 
tone may lead to an increased resting bronchomotor tone, which can be reduced by 
ipratropium bromide and by exercise. 
11) In adult CF patients with bronchial hyperresponsiveness, the daily inhalation of 1600 
meg budesonide for six weeks induces a small but significant improvement in bronchial 
responsiveness to histamine and reduces symptoms of cough and dyspnoea. 
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Chapter 11 
Samenvatting, conclusies en overwegingen. 

Cystic fibrosis (CF) is de meest voorkomende erfelijke ziekte met fatale afloop bij 
blanke mensen. Door verbetering in de therapie wordt de levensverwachting van kinderen 
hoger en velen bereiken tegenwoordig de volwassen leeftijd. Longartsen en maag,darm 
en lever-artsen krijgen daardoor in toenemende mate te maken met de zorg voor volwas-
sen CF patiënten. De meeste morbiditeit wordt veroorzaakt door complicaties op pulmo-
naal en intestinaal gebied. Uiteindelijk sterft meer dan 90 % van de CF patiënten door 
respiratoire insufficientie. Het is daarom belangrijk om functionele stoornissen van 
pulmonale en gastrointestinale aard vast te stellen en te behandelen waar nodig in een 
vroegtijdig stadium. 
In dit proefschrift worden een aantal aspecten beschreven van de functiestoornissen op 
pulmonaal en gastrointestinaal gebied bij volwassen patiënten. 
In Hoofdstuk 3 beschrijven we de resultaten van een retrospectieve studie naar gastro-
intestinale afwijkingen bij volwassen CF patiënten. Klachten en verschijnselen van ziekten 
van lever, pancreas, galblaas en darmkanaal traden zowel voor als na de eerste presentatie 
van de respiratoire problemen op. Exocriene pancreasinsufficientie was aanwezig in 80 % 
van de volwassen CF patiënten. Een aantal patiënten met normale faeces-vetexcretie 
hadden recidiverende pancreatitiden doorgemaakt en het lijkt raadzaam om bij jonge 
patiënten met onverklaarde recidiverende pancreatitis de diagnose CF te overwegen. 
Tekorten aan de vetoplosbare vitamines D en E waren aanwezig bij de meeste patiënten 
met steatorroe. Bij 20 % van de patiënten werden episoden van het distale intestinale 
obstructie syndroom (DIOS) geconstateerd. Adequate diagnostiek en therapie zijn 
belangrijk voor deze potentieel gevaarlijke intestinale afwijking. Leverfunctiestoornissen 
werden bij vele patiënten vastgesteld, maar leve rei rrose was slechts aanwezig bij 2-5 % 
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van de volwassen CF patiënten. De leverafwijkingen kunnen het eerste verschijnsel zijn 
van de ziekte CF. Diagnostiek en therapie van leverafwijkingen door CF zijn onderwerp 
van discussie in hoofdstuk 3. 
In Hoofdstuk 4 wordt de literatuur met betrekking tot pulmonale ziekten bij CF bespro-
ken. Er is grote variabiliteit in de ernst van de longafwijkingen en de snelheid waarmee 
de longfunctie achteruit gaat. De longfunctiestoornissen lopen parallel met de palhofysio-
logische processen. Bactericlc infectie en kolonisatie dragen bij aan exacerbaües en 
longfunctieverlies. De rol van virale en mycobacteriele infecties is nog controversieel. 
Belangrijke pulmonale complicaties bij CF betreffen hemoptoe, pneumothorax en 
allergische bronchopulmonale aspergillose. De behandeling van deze complicaties wordt in 
hoofdstuk 4 besproken. De effecten van bronchusverwijdende medicatie en de aanwezig-
heid van bronchiale hyperreactiviteit zijn onderwerp van discussie in de hoofdstukken 7 en 
8.De vooruitgang in de genetische kennis omtrent CF biedt perspectieven voor causale en 
gen-therapeutische benaderingen in de toekomst. Longtransplantatie is een belangrijke 
optie geworden voor geselecteerde CF patiënten. Het betekent echter geen genezing en 
zorgvuldige bewaking van pulmonale en intestinale afwijkingen blijft ook bij deze 
patiënten noodzakelijk. 
In Hoofdstuk 5 werd onderzoek gedaan naar de exocriene en endocriene functiestoor-
nissen en morfologische karakteristieken van het pancreas bij volwassen CF patiënten in 
vergelijking met gezonde conlrolepersonen. Echografisch onderzoek Het een vergroot 
caput pancreaticum en een smal corpus pancreaticum zien bij de CF patiënten. Blijkbaar 
treedt het beschadigende effect van het pathofysiologisch proces meer in het corpus 
pancreaticum op, waarbij het caput pancreaticum initieel relatief gespaard blijft. Deze 
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gedachte wordt gesteund door de bevinding dat bij selenomethionine scanning alleen het 
caput pancreaticum van CF patiënten uptake vertoont. De pancreaspolypeptide (PP) 
spiegels voor en na voedselinname waren sterk verlaagd bij alle CF patiënten. Bij 
patiënten met chronische pancreatitis daarentegen is de PP secretie vaak normaal totdat de 
pancreas dusdanig beschadigd is dat steatorroe optreedt. De plasma PP spiegels voor en 
na voedselinname correleerden bij de CF patiënten goed met de echografisch bepaalde 
diameters van het caput pancreaticum. Dit duidt er op dat atrofie, fibrose en vervetting 
van het pancreas gepaard gaan met een vroegtijdige afname in aantal en/of functie van de 
PP cellen. Bij de CF patiënten bleek verder de insulinesecretie na een maaltijd significant 
vertraagd te zijn. De insuline-producerende cellen zijn wel minder gevoelig voor de 
beschadigende processen in het pancreas dan de PP cellen en het exocriene pancreasweef-
sel. De excretie in de urine van n-paraaminobenzoezuur (n-PABA) bleek verlaagd bij CF 
patiënten zowel met als zonder steatorroe. Uit studies met de secretinc-cholecystokinine 
stimulatietest bleek dat, onafhankelijk van de pancreasenzymproductie, bij CF patiënten de 
productie van vocht en bicarbonaat door het pancreas gestoord was. Om deze discrepan-
tie tussen acinaire en ductulaire pancreasfunctie vast te stellen zijn stimulatietesten met 
zowel secretine als cholecystokinine noodzakelijk. Het vaststellen van karakteristieke 
afwijkingen door middel van echografisch, exocrien en endocrien pancreas functieonder-
zoek kan een hulpmiddel zijn om de diagnose CF te stellen bij niet-informatieve zweet-
tests. Chromosomaal onderzoek heeft hierbij uiteraard ook een belangrijke plaats. Voor de 
algemene praktijk is het van belang om bij de behandeling van volwassen CF patiënten 
regelmatig steatorroe, deficiënties van vetoplosbare vitamines en eventuele hyperglykemie 
te onderzoeken. 
147 
Cholelithiasis is een andere frequente complicatie van CF, aanwezig bij 6-30 % van de 
volwassen patiënten. Een verminderde plasma cholecystokinine (CCK) secretie en 
galblaascontractie kunnen zowel bijdragen aan de vet- maldigestie als aan de vorming van 
galstenen. Lage plasma CCK spiegels en een verminderde galblaasontlediging werden 
recent ook vastgesteld bij patiënten met ernstige pancreasinsufficientie ten gevolge van 
chronische pancreatitis. Om deze reden bepaalden wij de plasma CCK spiegels en 
galblaasvolumina voor en na het nuttigen van een procfmaaltijd bij volwassen CF patiën-
ten, alsmede een controlegroep van normale personen. De resultaten van deze studie 
werden besproken in hoofdstuk 6. Bij de CF patiënten bleken de plasma CCK spiegels 
voor en na voedsclinname significant hoger dan bij de controlepersonen. Zeer waarschijn-
lijk zijn deze verhoogde CCK spiegels niet het gevolg van een verminderde intraluminal 
pancreasenzymactiviteit maar van verminderde feedback inhibitie van CCK-producerende 
cellen door intraluminal galzuren. De plasma CCK spiegels zijn bij de mens omgekeerd 
evenredig aan de hoeveelheid galzuren in de dunne darm. Een kleinere galzuurpool en een 
verminderde output van galzuren naar het duodenum kunnen de observatie van toegeno-
men plasma CCK spiegels bij de CF patiënten verklaren. Het is mogelijk dat verhoogde 
CCK spiegels betrokken zijn in de Pathogenese van gastro-oesophageale reflux, dat bij CF 
patiënten in een verhoogde frequentie voorkomt, omdat bekend is dat CCK de druk in de 
onderste slokdarmsfincter verlaagt. De verhoogde plasma CCK spiegels bij CF patiënten 
werden vergezeld door afgenomen galblaasvolumina, zowel nuchter als na voedselinname. 
Kleinere galblaasvolumina kunnen bijdragen aan verkleining van de galzuurpool en 
vermindering van de totale galzuuroutput in het duodenum zoals bij CF patiënten is 
vastgesteld. De galblaasontlediging na voedselinname was intact bij de CF patiënten. 
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Noch een gestoorde plasma CCK secretie, noch een gestoorde galblaasontlediging lijken 
dus een rol te spelen bij maldigestie en galsteenvorming bij volwassen CF patiënten. 
In Hoofdstuk 7 worden studies besproken betreffende de longfunctie van volwassen CF 
patiënten gemeten met spirometrie, MEFV-curves en bodyplethysmografie. Bij de meeste 
patiënten was belangrijke bronchusobstructie aanwezig en bij 7 patiënten bestond eveneens 
een restrictieve longfunctiestoornis. Opvallend waren de verschillen tussen de totale long 
capaciteit (TLC) bepaald met bodyplethysmografie en de TLC gemeten met de heliumver-
dunningsmethode. Om deze verschillen te kwantificeren werd een "airtrapping-index" 
gedefinieerd. Deze index correleerde significant negatief met de MEF-50 en MEF-25 
waarden en positief met de RV/TLC ratio en weerspiegelt belangrijke airtrapping door 
perifere luchtwegobstructie. Eveneens werden de effecten bepaald van bronchusverwij-
dende medicatie in de vorm van terbutaline en ipratropium bromide bij de volwassen CF 
patiënten. MEFV-curves met kamerlucht en met He-02 (= heliox: 80 % helium en 20 % 
zuurstof) werden bepaald voor en na inhalatie van verschillende doseringen terbutaline en 
ipratropium bromide. Uit de MEFV-curves werd de density dependence van de expiratoire 
flow bepaald, uitgedrukt als delta-MEF-50. Zowel inhalatie van terbutaline als ipratropi-
um bromide veroorzaakten een significante dosis-gerelateerde bronchusverwijding. 
Klinisch relevante reversibiliteit, gedefinieerd als tenminste 15 % toename van de FEV-1 
na toediening van een bronchusverwijdend middel, was aanwezig bij 70 % van de patiën-
ten. De mate van bronchusverwijding verschilde niet tussen terbutaline en ipratropium 
bromide. De meeste volwassen CF patiënten bleken non-responder voor heliox ( delta 
MEF-50 < 20 % ), passend bij overwegend perifere luchtwegobstructie. Terbutaline 
veroorzaakte een significante en consistente toename van de delta MEF-50 terwijl 
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ipratropium bromide geen invloed had op de density dependence van de expiratoire flow. 
Terbutaline blijkt daarom vooral de perifere luchtwegen te verwijden terwijl ipratropium 
bromide waarschijnlijk verwijding van zowel centrale als perifere luchtwegen bewerkstel-
ligt. In tegenstelling tot hetgeen bij kinderen met CF is beschreven, zagen wij geen 
(paradoxaal) negatieve respons na inhalatie van bronchusverwijders bij de volwassen CF 
patiënten. 
Op basis van deze bevindingen is het raadzaam om bij CF patiënten de bronchusverwij-
dende effceten te bepalen van zowel 3-adrenoreceptor agonisten als muscarine receptoran-
tagonisten. 
In Hoofdstuk 8 werd onderzoek verricht naar de aanwezigheid van bronchiale 
hyperreactivitcit voor histamine. Tevens werden de effecten bepaald van inspanning, 
bronchusverwijders en de aanwezigheid van atopie bij volwassen CF patiënten. Hyperre-
activiteit voor histamine ( РС
М
 histamine < 8 mg/ml ) was aanwezig bij 56 % van de 
patiënten en beperkte zich niet tot hen met ernstige luchtwegobstructie. Bij de patiënten 
met hyperreactiviteit voor histamine was de bronchusverwijdende respons na terbulaline 
significant groter dan bij de patiënten zonder hyperreactiviteit voor histamine. Na 
inspanning op een tredmolen werd geen bronchoconstrictie waargenomen maar juist een 
toename van de FEV-1 en de MEF-50 waarden. Er bestond geen verband tussen de 
hyperreactiviteit na histamine en de reacties op inspanning. De toename in FEV-1 door 
inspanning was significant gecorreleerd aan de toename in FEV-1 na inhalatie van ipratro-
pium bromide. Bij CF patiënten is al eerder een toegenomen activiteit en reactiviteit van 
het cholinerge zenuwstelsel vastgesteld. Tevens zijn er aanwijzingen dat vagale reacties 
betrokken zijn bij het ontslaan van "exercise-induced asthma". Deze gegevens combine-
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rend, concluderen wij dat bij volwassen CF patiënten een toegenomen vagale tonus kan 
leiden tot een verhoogde bronchomotore rusttonus die verlaagd kan worden door zowel 
ipratropium bromide als door inspanning. Door middel van een standaard RAST test met 
10 inhalatie-allergenen werden positieve tests vastgesteld bij 50 % van de onderzochte 
volwassen CF patiënten. Deze patiënten hadden allen twee of meer positieve tests en 
werden beschouwd als atopisch. De longfunctie, hyperreactiviteit na histamine en de 
reactie op inspanning en bronchusverwijders waren niet verschillend tussen atopische en 
niet-atopische patiënten. Deze hoge incidentie van atopie kan wellicht verklaard worden 
door een toegenomen expositie aan allergenen in de luchtwegen, als gevolg van een 
gestoorde klaring van geïnhaleerde allergenen en een verhoogde permeabiliteit van de 
beschadigde bronchiale mucosa. Dit is in overeenstemming met de bevinding dat de 
frequentie van positieve huidallergietests toeneemt met de leeftijd van CF patiënten. De 
aanwezigheid van atopie bleek niet gerelateerd te zijn aan emst en/of prognose van CF. 
Hoewel interessant vanuit palhofysiologisch standpunt, is de aanwezigheid van atopie bij 
CF patiënten van weinig klinisch belang. 
Het onderliggende mechanisme van bronchiale hyperreactivitcit bij CF is onduidelijk. 
De aanwezigheid van hyperreactiviteit blijkt prognostish ongunstig te zijn voor CF 
patiënten. Het is mogelijk dat bronchiale hyperreactiviteit toeneemt met de leeftijd van CF 
patiënten. De hoge prevalentie van bronchiale hyperreactiviteit was reden om te bestude-
ren of inhalatiecorticosteroiden hierop invloed hebben. In hoofdstuk 9 worden de 
resultaten beschreven van een dubbel-blinde placebo-gecontroleerde cross-over studie naar 
de effecten van een inhalatiecorticosteroid, budesonide, op de longfunctie en bronchiale 
hyperreactiviteit van volwassen CF patiënten met aangetoonde hyperreactiviteit voor 
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histamine. Zestien patiënten werden behandeld met budesonide, 1600 mcg dagelijks, en 
met placebo gedurende twee perioden van zes weken. Het effect van budesonide werd 
beoordeeld aan de hand van histamincdrcmpels, spirometrie en klinische symptoomscores. 
Budesonide had geen significant effect op spirometrische parameters. De bronchiale 
hyperreactiviteit voor histamine verbeterde wel significant in vergelijking tot de uitgangs-
waarden. De geometrisch gemiddelde PC^ histamine steeg van 1,6 naar 3,2 mg/ml. Bij 
58 % van de patiënten steeg de РСщ histamine met meer dan een verdubbelings-dosis. 
Uit de dagelijkse symptoomscores bleek dat behandeling met budesonide leidde tot kleine, 
doch significante, verbeteringen in kortademigheid en hoesten. Steeds meer gegevens 
wijzen er op dat excessieve immunologische reacties bijdragen aan de schade die aan de 
long toegebracht wordt bij CF patiënten. Een behandeling met orale corticosteroiden 
bleek het klinisch beloop van een groep CF patiënten gunstig te beïnvloeden, doch was 
echter geassocieerd met onacceptabele bijwerkingen op langere termijn. Onze studie is de 
eerste waarin het effect van inhalatie-corticosteroiden bij CF patiënten prospectief 
onderzocht is. Langer durende observaties zijn noodzakelijk om vast te stellen of inhala-
tie-corticosteroiden de prognose van CF op de langere termijn verbeteren. 
Samengevat, beschrijft dit proefschrift onderzoeken naar de pulmonale en intestinale 
functiestoornissen die bij volwassen CF patiënten kunnen optreden. Diverse beschreven 
onderzoekmethoden kunnen worden uitgevoerd bij de individuele patient in de algemene 
praktijk en zijn behulpzaam voor een optimale behandeling van de volwassen CF patient. 
Tevens bieden zij perspectieven voor vervolgstudies in de toekomst: 
-Onderzoek naar de correlatie van morfologische veranderingen zoals vastgesteld met 
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obductiegegevens en beeldvormende technieken zoals high resolution computer tomograp-
hy scanning enerzijds en functionele stoornissen van longen en luchtwegen anderzijds. 
-Onderzoek naar de invloed en interactie van bronchusverwijdende geneesmiddelen en 
inhalatiecorticosteroiden op de lange termijn. 
De toegenomen overleving van CF patiënten en het herkennen van mildere vormen bij 
oudere patiënten impliceert dat meer longartsen en maag-, darm en lever-artsen betrokken 
zullen raken bij de behandeling en zorg voor deze gecompliceerde ziekte. De behandeling 
van CF patiënten dient plaats te vinden in gespecialiseerde centra waar de grotere ervaring 
met deze ziekte leidt tot betere zorg dan verleend kan worden in een regionaal ziekenhuis. 
In deze CF-centra kunnen medische expertise en onderzoek zich ontplooien. Hoewel 
ontwikkelingen op het gebied van de DNA-technoIogie en de longtransplantatie veelbelo-
vend zijn, blijft onderzoek en behandeling van pulmonale en intestinale functiestoornissen 
belangrijk voor het welzijn en de prognose van CF patiënten. 
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Algemene Conclusies 
1) Bij volwassen CF patiënten zijn kenmerkende afwijkingen aanwezig bij het exocriene 
en endocriene pancreasfunctie-onderzoek. 
2) De plasma cholecystokinine concentraties voor en na voedselinname zijn significant 
verhoogd bij volwassen CF patiënten. 
3) De verhoogde plasma cholecystokinine concentraties gaan gepaard met verminderde 
galblaasvolumina in zowel de nuchtere als postprandiale situatie. De postprandiale 
galblaasontlediging is normaal. 
4) De diagnose CF dient overwogen te worden bij jonge patiënten met onverklaarde 
recidiverende pancreatitis of levereirrose. 
5) Ten gevolge van opvallende airtrapping dient de bepaling van statische longvolumina 
bij CF patiënten bij voorkeur plaats te vinden met bodyplethysmografie. 
6) Bronchiale hyperreactiviteit voor histamine is aanwezig in een hoge frequentie bij 
volwassen CF patiënten en beperkt zich niet tot de patiënten met ernstige bronchusob-
structie. 
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7) Zowel inhalatie van 32-sympaticomimetica als muscarine receptor antagonisten 
veroorzaken dosis-gerelateerde bronchusverwijding bij volwassen CF patiënten. De 32-
sympaticomimetica blijken meer effect te hebben op de perifere luchtwegen, terwijl 
ipratropium bromide een meer gegeneraliseerde bronchusverwijding veroorzaakt. 
8) Bronchiale hyperreactiviteit voor histamine is bij volwassen CF patiënten gerelateerd 
aan de bronchusverwijdende respons op de beta-adrenoreceptor agonist terbutaline. 
9) De aanwezigheid van atopie bij volwassen CF patiënten geeft geen informatie over 
bronchiale hyperreactiviteit en lijkt van weinig klinisch belang. 
10) Bij volwassen CF patiënten veroorzaakt inspanning een bronchusverwijding zonder 
daaropvolgende bronchoconstrictie. De bronchusverwijding na inhalatie van ipratropium 
bromide correleert met deze bronchusverwijding na inspanning. Een verhoogde vagus 
tonus kan leiden tot een toegenomen bronchomotore rust-tonus, die afneemt door 
ipratropium bromide en door inspanning. 
11) Bij volwassen CF patiënten met aangetoonde bronchiale hyperrcactiviteit voor 
histamine, verbeteren de bronchiale hyperreactiviteit en symptomen van kortademigheid 
en hoesten na het dagelijks inhaleren van 1600 meg budesonide. 
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Nawoord 
Gaarne wil ik degenen bedanken die hebben bijgedragen aan de totstandkoming van dit 
proefschrift. 
De patiënten die bereidwillig hebben deelgenomen aan de verschillende onderzoeken. 
De medewerkers van het longfunctielaboratorium van het Academisch Ziekenhuis 
Nijmegen die enthousiast en zorgvuldig hebben geassisteerd tijdens de metingen. 
Prof dr G.Rosenbusch en de medewerkers van de Afdeling Radiodiagnostiek die de 
echografische metingen hielpen uitvoeren en beoordelen. 
De medewerkers van de functieafdeling van de Afdeling Maag-, Darm- en Leverziekten 
en het Klinisch Chemisch Laboratorium die assistentie verleenden bij de verrichte 
onderzoeken. 
Dr J H M van Tongeren voor zijn stimulerende hulp in de beginfase van de onderzoeken 
voor dit proefschrift. 
Prof dr J В M J Jansen en prof dr С В H W Lamers voor hun hulp en advies bij het 
onderzoek beschreven in de hoofdstukken 5 en 6. 
Dr Ρ G G Gerlag, opleider inteme geneeskunde in het St Jozef ziekenhuis te Veldhoven, 
die mij tijdens de opleiding niet alleen de ruimte en mogelijkheden bood om de verschil­
lende onderzoeken te verrichten, maar ook kritisch en positief zijn brede medische kennis 
en humor wist over te brengen. 
De longartsen (opleider dr С A F Jansveld) en de collega arts-assistenten van het 
Catharinaziekenhuis te Eindhoven die de ruimte boden om dit proefschrift af te ronden. 
De longartsen dr W Bakker, dr H Heijerman en dr С Groot van het Leyenburgziekenhuis 
te Den Haag die meegewerkt hebben aan de studie in hoofdstuk 9. 
Guy van Dael die hulp verleende voor het maken van dia's en de figuur van hoofdstuk 4. 
Ria Oerlemans voor haar hulp bij de laserprinter. 
Drs Johan Lummen voor zijn deskundige adviezen met betrekking tot het juiste gebruik 
van de Engelse taal. 
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Prof dr Cees van Herwaarden, Prof dr Jan-Willem Lammers en dr Wim Hopman die met 
niet aflatende steun, opbouwende kritiek en positieve discussies dit onderzoek gedurende 
jaren hebben begeleid. 
Mijn ouders, die mij in staat stelden geneeskunde te studeren. 
Marjon, mijn lieve echtgenote, die altijd naast mij, voor mij en achter mij staat. 
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De auteur van dit proefschrift werd geboren op 6 september 1962 in Hengelo (Ov). Hij 
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1980 tot 1987 studeerde hij geneeskunde aan de Katholieke Universiteit te Nijmegen. 
Tijdens deze studie werd een wetenschappelijke stage verricht met onderzoek naar de 
gastrointestinale aspecten van Cystische Fibrose waaruit de basis gelegd werd voor het 
uiteindelijke proefschrift. De scriptie van deze stage werd bekroond met de Parke Davis-
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vervolgd op 01-09-91 in het Catharinaziekenhuis te Eindhoven (opleider Dr CAF Jans-
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Kraft, geboren te Heerlen en werkzaam als bedrijfsarts bij de GGD Midden Brabant te 
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Stellingen behorende bij het 
proefschrift: Cystic Fibrosis in Adults: Functional investigations of the 
Pulmonary and Digestive System. 
1 De plasma cholecystokinine concentraties zijn verhoogd en de gal-
blaas volumina zijn verminderd voor en na voedselinname bij 
volwassen CF patiënten. (Dit proefschrift) 
2 Bronchiale hyperreactiviteit is in hoge frequentie aanwezig bij 
volwassen CF patiënten, is gecorreleerd met de bronchusverwijdende 
respons op beta-sympaticomimetica en vertoont geen samenhang met 
een allergische constitutie. (Dit proefschrift) 
3 Zowel beta-sympaticomimetica als anticholinergica veroorzaken dosis-
gerelateerde bronchusverwijding bij volwassen CF patiënten. (Dit 
proefschrift) 
4 De bronchusverwijding door toediening van ipratropium bromide 
correleert met de bronchusverwijding die veroorzaakt wordt door 
inspanning, hetgeen verklaart wordt door een toegenomen parasympa-
tische tonus in rust. (Dit proefschrift) 
5 "Dum Spiro, spero". (Zolang ik adem, hoop ik) 
(Cicero, 43 ν C, Atticus 9;10,3) 
6 Volwassen CF patiënten met hypoxemic in rust en bij inspanning 
kunnen zonder risico participeren in een klinisch trainingsprogramma 
met zuurstofsuppletie. De inspanningstolerantie kan hierdoor signi-
ficant verbeteren.(H.Heijerman,Thesis,1991) 
7 Het "primair anlifosfolipiden antistoffen syndroom" is een onderschatte 
oorzaak van recidiverende trombose en longembolie. (EHJ van Haren 
en AWAM van Rijthoven in Med J SJZ 1990;19:233-235) 
8 Followers of the CF story have just been reading a very exciting 
chapter. But they are not yet at the end of the book. (R.Knight, Br J 
Hosp Med 1992 47:502-506) 
9 Een patient verdenken van... betekent dat de arts de patient als een 
crimineel ziet. 
10 All I need is the air that I breathe. (Hollies,1974) 
11 Tsuru No Sugomori,-"Het insluiten van de kraanvogels in hun nest", is 
een gracieuze beëindiging van het Go-spel. (Shibumi) 
12 De strategische positie van Lesotho ten opzichte van Zuid Afrika heeft 
geleid tot een overmaat aan ontwikkelingshulp die het land in te hoge 
mate daarvan afhankelijk heeft gemaakt, hetgeen de verzelfstandiging 
belemmert. (Eigen waarneming, FMP van Haren) 
13 Het baltsgedrag van de volwassen vrouwelijke Agapornis papagaai 
vertoont grote overeenkomsten met een acute aanval van hyperventila-
tie. (Eigen waarneming) 
14 Amor Tussisque Non Celatur. (Liefde en hoest kun je niet verbergen) 
(Erasmus) 
E.H.J. van Haren, maart 1994. 


